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1 Summary 
FAT1 is a member of the atypical cadherin FAT subfamily. The first identified 
member of this family was Drosophila Fat which has been regarded as a tumor 
suppressor because of its implication in tissue growth. In vertebrates FAT 
subfamily consists of 4 members, FAT1, -2, -3 and FAT-J (or FAT4). Only FAT1 
has so far been studied more intensively. FAT1 is expressed in a wide range of 
tissues and a homozygous knockout for FAT1 in mice was perinatal lethal. In vitro 
studies indicate that it is involved in cell polarity and migration. Cancer research 
revealed deregulated FAT1 expression. In some tumors as breast cancer FAT1 is 
over-expressed while FAT1 expression is reduced or deleted in others as 
astrocytic tumors or cholangiocarcinoma. 
In the present work, we first analyzed the role of FAT1 in chronic liver disease. We 
found FAT1 upregulation in a murine model of non-alcoholic steatohepatitis 
(NASH) and could confirm this result in human tissue from NASH patients. 
Moreover, we detected induced FAT1 expression in further murine models of 
chronic liver injury. Thus, bile duct ligation (BDL) as well as hepatotoxic 
thioacetamide (TAA) administration induced hepatic upregulation of FAT1 
expression. Furthermore, FAT1 expression was significantly heightened in cirrhotic 
human liver tissue. Activated hepatic stellate cells (HSC) were identified as the 
main cellular source of FAT1 in chronic liver disease. Suppression of FAT1 by 
siRNA inhibited NFκB activation and thereto proinflammatory gene expression, 
and reduced apoptosis resistance in activated HSC. 
Next, we investigated FAT1 expression and function in hepatocellular carcinoma 
(HCC). FAT1 expression was significantly upregulated in HCC cell lines as well as 
in HCC tumor tissue compared to primary human hepatocytes (PHH) and non-
tumorous liver tissue. In human HCC tissues strong FAT1 expression correlated 
with tumor stage and proliferation rate. Stable suppression of FAT1 by shRNA 
transfection reduced proliferation as well as migratory potential of HCC cells. 
Moreover, cells with suppressed FAT1 expression demonstrated higher 
susceptibility towards apoptosis, induced by serum starvation. To evaluate the role 
of FAT1 in HCC in vivo we injected stable FAT1 suppressed cells into nude mice. 
We observed delayed tumor onset and more apoptotic cells in tumors derived from 
FAT1 suppressed cell clones.  
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Finally, we searched for mechanisms responsible for FAT1 upregulation in HCC. 
We found that hepatocyte growth factor (HGF), a factor secreted by activated 
HSCs, induced FAT1 expression in vitro. FAT1 expression was further increased 
in HCC cells under hypoxia, and this induction was strongly repressed by inhibition 
of hypoxia inducible factor 1 alpha (HIF1α). Hypoxia caused significantly reduced 
levels of the methyl group donor S-adenosylmethionine (SAM), and SAM 
supplementation inhibited the hypoxia induced FAT1 expression in HCC cells. 
Conversely, demethylating agents induced FAT1 expression in HCC cells, and 
expression analysis in 24 human HCC tissues showed a significant correlation 
between FAT1 and MAT2A, which is known to critically affect SAM levels in HCC.  
In conclusion, increased FAT1 expression in chronic liver disease and HCC 
functionally promotes the course of disease and thereto may be a new therapeutic 
target for the prevention and treatment of hepatic fibrosis in chronic liver disease 
and hepatocellular carcinoma. 
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1.1 Zusammenfassung 
 
FAT1 ist ein Mitglied der atypischen Cadherin-Subfamilie FAT. Das erste 
identifizierte Mitglied dieser Familie war Drosophila Fat. Dieses wurde aufgrund 
seiner Funktion im Gewebewachstum als Tumorsuppressor angesehen. In 
Vertebraten besteht die FAT Subfamilie aus 4 Mitgliedern: FAT1, -2, -3 und FAT-J 
(FAT4), von denen nur FAT1 genauer erforscht wurde. FAT1 wird in vielen 
Geweben exprimiert. Ein homozygoter Knockout von FAT1 in Mäusen ist perinatal 
letal. In vitro Studien zeigten, dass FAT1 an der Zellpolarität und Migration beteiligt 
ist. In der Krebsforschung wurde eine deregulierte Expression von FAT1 
gefunden. In einigen Tumoren, wie z.B. im Brustkrebs, ist FAT1 überexprimiert, 
wohingegen in anderen Tumoren, wie z.B. in astrozytären Tumoren oder im 
Cholangiokarzinom, eine verminderte FAT1 Expression vorliegt. 
In dieser Arbeit analysierten wir zuerst die Rolle von FAT1 bei chronischen 
Lebererkrankungen. Eine Hochregulation von FAT1 konnte in einem murinen 
Modell der Nicht-Alkoholischen-Steatohepatitis (NASH) festgestellt werden. Diese 
Ergebnisse wurden in humanen Geweben von NASH Patienten bestätigt. 
Desweiteren fanden wir eine induzierte FAT1 Expression in murinen chronischen 
Leberschädigungsmodellen. Die Gallengangsligation (bile duct ligation, BDL) 
sowie die Gabe von hepatotoxischem Thioacetamid (TAA) führten zu einer 
erhöhten FAT1 Expression. Außerdem konnte eine signifikante Hochregulation der 
FAT1 Expression in humanen zirrhotischen Lebergeweben gefunden werden. Als 
Hauptquelle für FAT1 in chronischen Lebererkrankungen wurden aktivierte 
hepatische Sternzellen (HSC) identifiziert. Die Suppression von FAT1 in 
aktivierten HSC mittels siRNA inhibierte die NFκB Aktivierung und verminderte 
dadurch sowohl die Expression von proinflammatorischen Genen als auch die 
Apoptoseresistenz.  
Weiterhin beschäftigt sich diese Arbeit mit der Expression und Funktion von FAT1 
im hepatozellulären Karzinom (HCC). Die FAT1 Expression in HCC Zelllinien 
sowie in HCC Tumorgeweben war im Vergleich zu primären humanen 
Hepatozyten (PHH)  und nicht-tumorigenen Lebergeweben signifikant 
hochreguliert. In humanen HCC Geweben korrelierte eine starke FAT1 Expression 
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mit dem Tumorstaging und der Proliferationsrate. Die stabile Suppression von 
FAT1 mittels shRNA Transfektion verminderte die Proliferation sowie die Migration 
von HCC Zellen. Außerdem zeigten HCC Zellen mit supprimierter FAT1 
Expression eine erhöhte Suszeptibilität gegenüber der durch Serumentzug 
induzierten Apoptose. Um die Rolle von FAT1 im HCC in vivo zu untersuchen 
injizierten wir stabil FAT1-supprimierte HCC Zellen in Nacktmäuse. Wir konnten 
feststellen, dass Tumoren aus FAT1-supprimierten Zellklonen später auftreten und 
mehr apoptotische Zellen enthalten als Tumoren aus Kontrollzellen. 
Schließlich sollten Mechanismen gefunden werden, die für die FAT1 
Hochregulation im HCC verantwortlich sind. Es konnte gezeigt werden, dass der 
Hepatozyten Wachstumsfaktor (hepatocyte growth factor, HGF), der von 
aktivierten HSCs sekretiert wird, die FAT1 Expression in vitro induziert. Die FAT1 
Expression in HCC Zellen konnte weiterhin durch Hypoxie verstärkt werden. Diese 
Induktion wurde durch Inhibition des Hypoxie induzierten Faktors 1 alpha (HIF1α) 
stark vermindert. Hypoxie führte zu signifikant verminderten Level des 
Methylgruppen-Donors S-Adenosylmethionin (SAM) und die Supplementation von 
SAM inhibierte die durch Hypoxie induzierte FAT1 Expression in HCC Zellen. 
Demethylierende Agenzien induzierten dagegen die FAT1 Expression in HCC 
Zellen. Durch Expressionsanalysen in 24 humanen HCC Geweben konnte eine 
signifikante Korrelation zwischen FAT1 und MAT2A gefunden werden. Von 
MAT2A ist bekannt, dass es die SAM Level entscheidend beeinflusst.  
Zusammenfassend lässt sich feststellen, dass die erhöhte FAT1 Expression in 
chronischen Lebererkrankungen und im HCC das Fortschreiten der Erkrankung 
fördert. Daher könnte FAT1 ein neues therapeutisches Ziel für die Prävention und 
die Behandlung der hepatischen Fibrose sowie des HCC darstellen. 
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2 Introduction 
2.1 Liver 
2.1.1 Anatomy 
The liver is the largest parenchymal organ and the largest gland in the human 
body and located in right upper quadrant in the abdominal cavity just below the 
diaphragm, shielded by the costal arch. Macroscopically, the liver can be 
subdivided into four different lobes (Lobus hepatis dexter, Lobus hepatis sinister, 
Lobus quadratus, and Lobus caudatus) and is surrounded by connective tissue, 
the so called Glisson’s capsule, which is linked to the intrahepatic connective 
tissue.  
The liver is supplied with two blood vessels: the Arteria hepatica propria brings 
arterial oxygenated blood, and the Vena portae hepatis transports venous, but 
nutrient-rich blood, drained from the gastrointestinal tract. Blood outflow is 
accomplished via the liver sinusoids by the Vena hepatica to the Vena cava 
inferior.  
2.1.2 Histology and function  
Microscopically, the liver can be further divided into hepatic lobules consisting 
mostly of hepatocytes and containing a vein in the center (Vena centralis). In the 
contact area of several lobules the periportal field includes Arteria and Vena 
interlobularis, as well as bile ducts (Ductuli interlobulares) also known as Glisson’s 
triangle. 
Hepatocytes represent the main cell type of the liver and are divided by liver 
sinusoids, built by fenestrated, discontinuous endothelium without basal 
membrane. Kupffer cells are specialized macrophages sitting in the walls of the 
sinusoids. A 10 to 15 µm wide perisinusoidal space, the space of Disse, is found 
between hepatocytes and sinusoids. It contains blood plasma and hepatic stellate 
cells (HSC, also called Ito cells). HSCs store lipids and vitamin A (Figure 2.1). 
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Figure 2.1 Graphical overview of the different liver cell types and their localization [modified from 
(Friedman and Arthur 2002)]. 
 
Being the central organ for metabolism and detoxification gives the liver specific 
tasks. It performs carbohydrate metabolism and thereby regulates blood glucose 
level in dependency on insulin and glucagon. Moreover, the liver takes part in lipid 
metabolism by the breakdown of lipids to free fatty acids and glycerol (lipolysis) 
and fatty acid as well as triglyceride synthesis (lipogenesis). Cholesterol is 
oxidized by the liver and can be discarded as bile acids. Further, the liver builds 
plasma proteins like albumin and coagulation factors and is involved in amino acid 
metabolism. During the degradation of amino acids ammonia is generated and will 
be used by the synthesis of urea. Additional functions of the liver are 
biotransformation of xenobiotica and for example heme and storage of iron.  
2.2 Liver disease 
Liver disease can be classified into acute and chronic liver disease. Acute liver 
injury can be induced by acute infections or intoxications. This rarely results in 
complete liver failure thanks to the regenerative response of the liver. 
Development of chronic liver disease upon ongoing hepatic injury is characterized 
by chronic hepatic inflammation which can contribute to liver fibrosis and ultimately 
cirrhosis. 
2.2.1 Liver fibrosis 
Liver fibrosis represents a wound healing process of the liver that leads to an 
excessive deposition of extracellular matrix (ECM) (Bataller and Brenner 2005; 
Friedman 2003). Major groups forming the properties of ECM are collagens, 
elastin, structural glycoproteins, and proteoglycans (Martinez-Hernandez and 
Introduction  7 
Amenta 1995). Accumulation of ECM is either evolved from overproduction, 
deficient degradation or both. Current evidence indicates that HSC are central 
mediators of fibrogenesis (Friedman 2004; Friedman 2008).  
Quiescent HSC are located in the space of Disse (see chapter 2.1) and constitute 
the main storage location for vitamin A. Upon hepatic injury, HSC transform to an 
activated myofibroblast-like phenotype (Pinzani 1995), which express α-smooth 
muscle actin (α-sma) and show enhanced proliferation, contractility, fibrogenesis, 
and proinflammatory signaling. 
Fibrogenesis is characterized by deregulation of ECM remodeling with increased 
ECM deposition. Activated HSC secrete large amounts of collagen, predominantly 
the fibril-forming collagen I. Its expression is enhanced by activated gene 
transcription and on posttranscriptional level by increased mRNA stabilization 
(Stefanovic et al. 1997). Furthermore, the equilibrium between deposition and 
degradation of ECM is disordered. In healthy liver, matrix metalloproteinases 
(MMPs) are able to digest fibrotic scar tissue. MMPs are blocked by tissue 
inhibitors of matrix metalloproteinases (TIMPs), and upon activation HSCs show 
changes in the expression pattern of these enzymes. It has been shown that 
TIMP-1 expression is enhanced in response to liver injury, which prevents 
degradation of ECM (Benyon et al. 1996). 
Moreover, activated HSCs are characterized by high resistance to apoptosis. They 
survive prolonged serum deprivation as well as established pro-apoptotic stimuli 
like e.g. Fas ligand (Novo et al. 2006).  
One key transcription factor in the activation of hepatic stellate cells is NFκB. This 
signaling pathway is mediating apoptosis resistance (Oakley et al. 2005; Watson 
et al. 2008). But also, NFκB induces proinflammatory gene expression such as 
MCP1 and RANTES (Elsharkawy and Mann 2007; Hellerbrand et al. 1998; 
Schwabe et al. 2003).  
2.2.2 Liver cirrhosis 
The most advanced stage of fibrosis is cirrhosis. It is characterized by loss of liver 
function upon change of liver architecture. Nodules of regenerating hepatocytes 
and fibrotic septa are formed and replace normal parenchyma, which leads to 
hepatocellular dysfunction and obstruction of hepatic blood flow. The 
consequences are development of portal hypertension and hepatic insufficiency 
(Iredale 2003). Further complications are ascites, gastroesophageal varices, 
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bleeding resulting from decreased production of coagulation factors, hepatic 
encephalopathy and many more (Schuppan and Afdhal 2008). Moreover, 
presence of liver cirrhosis is the main risk factor for the development of HCC 
(Farazi and DePinho 2006). 
2.3 Causes for chronic liver disease 
2.3.1 Alcohol 
Chronic alcohol abuse is a major cause of chronic liver disease in Western 
countries. Alcohol consumption of over 20 g/day for women and 40 g/day for men, 
respectively, can cause alcoholic liver disease (Gramenzi et al. 2006). Fatty liver 
develops in more than 90% heavy drinkers, about 30% develop more severe 
forms, such as fibrosis and cirrhosis, and approximately 1-2% of alcoholic 
cirrhotics develop HCC each year (Gao and Bataller 2011; Seitz and Stickel 2007). 
Important mechanisms contributing to the pathogenesis of alcoholic liver disease 
are alcohol induced hepatotoxicity due to formation of acetaldehyde/acetate and 
oxidative stress in consequence of formation of reactive oxygen species (ROS). 
Further, production of cytokines results in immune response and infiltration of 
immune cells. In this stage, disease has progressed to steatohepatitis. Upon both, 
ROS and cytokine release, HSCs become activated and development of fibrosis 
initiates (De Minicis and Brenner 2008).  
2.3.2 Drug induced liver injury 
Since one function of liver is metabolizing xenobiotics (see chapter 2.1.2), it is 
obvious that drug-induced liver disease is a frequent complication of 
pharmaceuticals. Acute liver failure (ALF) is the worst consequence leading to 
death or requiring liver transplantation. More than half of all cases of ALF in the 
U.S. are caused by drugs, and the majority (39%) is provoked by acetaminophen 
(paracetamol). However, more than 10% of ALF are called idiosyncratic, which 
means that hepatotoxicity occurs only infrequently in between 1 in every 1,000 
patients to 1 in every 100,000 patients (Ostapowicz et al. 2002).  
Pathology of drug-induced liver disease covers a broad spectrum, from acute 
hepatic necrosis, chronic hepatitis, cholestasis to neoplasms and depends on 
different mechanisms of hepatotoxicity, e.g. cell death resulting from direct binding 
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of the drug to cell proteins, disorganization of the cytoskeleton, and blockage of 
the mitochondrial function (Navarro and Senior 2006). 
2.3.3 Autoimmune-related and genetic disorders 
Liver disease can also be effected by autoimmune disorders. Autoimmune 
hepatitis (AIH) is a generally progressive, chronic hepatitis with fluctuating course 
(Krawitt 2006). Further, primary biliary cirrhosis (PBC) and primary sclerosing 
cholangitis (PSC) are cholestatic liver disease based on autoimmune related 
mechanisms (Boonstra et al. 2012). Moreover, genetic defects may affect liver. 
Patients with Gilbert’s disease show reduced activity of UDP-
glucuronosyltransferase (UGT1A), and therefore, they have increased bilirubin 
serum levels and jaundice. Accumulation of copper in liver and brain is 
characteristic for Wilson’s disease, an autosomal recessive genetic disorder 
caused by mutations in the ATP7B gene (Ala et al. 2007). Similarly, in 
hemochromatosis the liver is harmed by iron overload. There are different forms of 
hereditary hemochromatosis with mutations in four diverse genes involved in iron 
metabolism (HFE, HJV, HAMP, TfR2) (Pietrangelo 2004). Further genetic 
disorders involving the liver are α1-antitrypsin deficiency, glycogen storage 
disease, and cystic fibrosis.  
2.3.4 Viral hepatitis 
Viral hepatitis is the consequence of infection with hepatitis virus A-E. Most 
relevant forms are presented below. 
2.3.4.1 Hepatitis A 
Hepatitis A is caused by the hepatitis A virus (HAV), a non-enveloped RNA virus 
and member of the Picornaviridae family. The predominant way of spreading is 
enteric transmission (faecal-oral) via person-to-person, or by consumption of 
contaminated water or food (e.g. bivalve molluscs). Areas of high endemicity are 
Asia, Africa, and Central and South America (Koff 1998). 
Incubation period is 15-50 days and symptoms of acute infection may be fatigue, 
nausea, vomiting, and fever. Later on, there may be patients with cholestatic 
symptoms like jaundice and dark colored urine. Symptoms usually last less than 
two months and infection never takes chronic course. However, less than 1% of all 
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hepatitis A patients show a severe course of the disease with acute liver failure. 
Prevention of HAV infection is possible because HAV vaccines are available.  
2.3.4.2 Hepatitis B 
Hepatitis B virus (HBV) is an enveloped DNA virus and belongs to the 
Hepadnaviridae virus family. The genome is replicated by utilization of a reverse 
transcriptase. Hepatitis B infection is one of the most common infectious diseases 
in the world, and virus transmissions occur percutaneously, sexually, and 
perinatally. High endemic regions are China, South East Asia, and sub-Saharan 
Africa. Because of its envelope HBV is quite stable and it shows high resistance to 
disinfectants, but a safe vaccination with active immunization exists (Lavanchy 
2004).  
Around one-third of infections proceed asymptomatically, the other patients have 
symptoms after an incubation time of 45 to 120 days. Symptoms are similar to 
HAV infection and typical for acute virus hepatitis. 0.5-1% of all HBV infections 
take severe course with fulminant hepatic failure. More than 90% of infections are 
self-limiting and patients have acquired lifelong immunity against HBV. In up to 
10% of patients virus infection persists and they suffer a chronic infection, which is 
a risk factor for developing cirrhosis and HCC (Dandri and Locarnini 2012). 
2.3.4.3 Hepatitis C 
The hepatitis C virus (HCV) is a member of the Flaviviridae family, comprising 
enveloped RNA virus. Transmission is possible by direct blood contact and 
perinatal from mother to child, in fewer cases also by sexual contact. High rates of 
chronic infection are found in Egypt, Pakistan and China. No protecting vaccine 
exists to date. Therefore, prevention of exposition is critical.  
75% of all infected persons have no or no specific symptoms, and thereto virus 
infection is often not diagnosed. Only 25% of HCV infections cause mild hepatitis 
symptoms. Persistence of HCV infections occurs in the majority of HCV-infected 
individuals, leads to chronic liver damage and may cause fibrosis, cirrhosis and 
HCC (Bartosch et al. 2009). 
2.3.4.4 Hepatitis D 
Hepatitis D occurs only in individuals positive for the HBV surface antigen, seen as 
hepatitis delta virus (HDV) is a satellite virus, which is defective and requires a 
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coinfection with HBV for its replication. Hence, immunization against HBV also 
protects from a HDV infection. Acute HBV and HDV coinfection is more severe 
than HBV infection alone, and chronic HDV infection takes a more progressive 
course than HBV monoinfection (Wedemeyer and Manns 2010) 
2.3.4.5 Hepatitis E 
Hepatitis E is provoked by infection with hepatitis E virus (HEV), which forms the 
Hepeviridae family. HEV is a non-enveloped RNA virus and is shown to be 
transmitted via the oral-faecal route or by contaminated water. Clinically, HEV 
infection is comparable to hepatitis A, but develops to acute, severe liver disease 
in some cases, especially in pregnant women. Chronic HEV infection is described 
in organ transplanted patients (Wedemeyer et al. 2012). 
2.3.5 Non-alcoholic fatty liver disease (NAFLD) 
2.3.5.1 Definition and prevalence of NAFLD 
It has been known for a long time that fatty livers of obese people can develop 
inflammation and fibrosis, but the term “non-alcoholic steatohepatitis (NASH)” has 
been introduced by Ludwig et al. (Ludwig et al. 1980). It describes hepatic 
steatosis and liver inflammation in patients without (significant) alcohol 
consumption. Meanwhile, the term “non-alcoholic fatty liver disease (NAFLD)” also 
includes fatty liver without hepatitis.  
NAFLD can take a progressive course starting from hepatic steatosis, which is 
characterized by deposition of triglycerides as lipid droplets in hepatocytes, 
following the development of NASH with ballooning of hepatocytes and cell death.  
Prevalence of NAFLD is estimated to be 20-30% in Western countries (Bedogni et 
al. 2005; Browning et al. 2004). The percentage of NAFLD patients is higher in 
obese people (57.5-74%) (Angulo 2002). In children prevalence of NAFLD is also 
increased in presence of obesity (Schwimmer et al. 2006). Moreover, advancing 
age is a risk factor for developing NAFLD (Frith et al. 2009).  
Strong associations between NAFLD and obesity, insulin resistance, hypertension, 
as well as dyslipidaemia have been found and are the origin for considering 
NAFLD as the liver manifestation of the metabolic syndrome (de Alwis and Day 
2008). 
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2.3.5.2 Etiology and pathogenesis 
Day and James described a two-hit-model for the pathogenesis of NAFLD (Day 
and James 1998). The ‘first hit’ arises from an imbalance between lipid acquisition 
and removal and leads to hepatic fibrosis. Subsequently, a ‘second hit’ induces 
inflammation. This includes oxidative stress due to increased lipid oxidation and 
deregulated cytokine production and results in steatohepatitis. But since NASH 
doesn’t show progression to fibrosis and cirrhosis in every patient, a ‘third hit’ 
appear to be necessary.  
2.3.5.3 Prognosis and therapy 
Prognosis of simple steatosis is good, but 20-30% of patients with NASH develop 
hepatic fibrosis and 10-30% evolve cirrhosis within 10 years (Argo et al. 2009; 
Argo and Caldwell 2009). This NASH induced cirrhosis is further a risk factor for 
HCC.  
Exercise, weight loss (diet-induced or by bariatric surgery) and treatment of the 
metabolic syndrome are recommended therapies since no established 
pharmacological treatment of NAFLD exists. 
2.4 Liver cancer 
The liver can be affected by metastatic cancer especially by spreading tumors of 
the gastrointestinal tract, breast, lung, pancreas and by malignant melanoma. 
Primary liver cancer is arising from liver cells and can be classified into different 
groups. Hepatocellular carcinoma (see chapter 2.4.1) and cholangiocarcinoma, a 
malignant tumor developing from the biliary tract represent 10%-25% of primary 
hepatic malignancies (Tyson and El-Serag 2011). Quite rare is the embryonal 
hepatoblastoma. Besides, there exist the mesenchymal angiosarcoma of the liver, 
a neoplasm of endothelial blood vessel cells forming 2 % of all primary liver tumors 
(Maluf et al. 2005). 
2.4.1 Hepatocellular carcinoma 
2.4.1.1 Prevalence and incidence 
Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide with 
around 700,000 newly diagnosed cases per year and the most frequent form of 
primary liver cancer with about 85%-90% (El-Serag and Rudolph 2007; Forner et 
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al. 2012). Because of its high lethality it is the third most common cause of death 
from cancer worldwide. The disease is more frequent in men than in women, and 
highest occurrence rates are reported for Eastern and Southeastern Asia (Ferlay 
et al. 2010). But the incidence of HCC is increasing in developed countries. 
Reasons may be rising rates of HCV infections (see chapter 2.3.4) and non-
alcoholic steatohepatitis (NASH, see chapter 2.3.5) as a consequence of diabetes 
and obesity (Venook et al. 2010). 
2.4.1.2 Etiology 
Hepatocarcinogenesis is a multi-step process based on cycles of inflammation, 
necrosis, oxidative stress and regeneration leading to genomic instability and 
epigenetic changes (Farazi and DePinho 2006). HCC mostly arises from an 
established background of chronic liver disease and cirrhosis (80%-90%), and the 
5-year cumulative risk for developing HCC in patients with cirrhosis ranges from 
between 5% and 30% (El-Serag 2011). Cirrhosis is mostly caused by chronic HBV 
or HCV infection, chronic alcohol abuse or NASH. Less common causes include 
hereditary hemochromatosis, Wilson’s disease, and α-1 antitrypsin deficiency (see 
chapter 2.3). 
Another risk factor for HCC in tropical regions is intoxication with aflatoxin 
produced by the fungus Aspergillus fumigatus via contamination of food grains (El-
Serag and Rudolph 2007). 
2.4.1.3 Therapy and prognosis 
Despite new strategies for the therapy, HCC remains a disease with poor 
prognosis attributed to frequently late diagnosis and aggressive tumor growth. A 
meta-analysis revealed a one year survival rate of 17.5% for untreated HCC 
patients (Cabibbo et al. 2010).  
Resection of the tumor is the first choice of treatment for patients without cirrhosis 
because of their limited liver function. However, risk for recurrence of HCC is quite 
high with about 70% of the patients with tumor remission within 5 years (Forner et 
al. 2012). Another surgical option is liver transplantation, which seems to be 
optimal curing tumor and cirrhosis simultaneously. However, drawbacks are organ 
shortage and lifelong immunosuppression. And also in this case the risk of tumor 
recurrence is approximately 20%. (Zimmerman et al. 2008).  
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Different forms of ablation are possibilities to treat HCC, even while awaiting 
transplantation or to make the tumor resectable. Ablation destroys tumor tissue by 
modifying the temperature of neoplastic cells (e.g. radiofrequency ablation, RFA) 
or by using chemical substances (e.g. percutaneous ethanol injection, PEI) 
(Gervais and Arellano 2011). 
Transarterial chemoembolization (TACE) is another therapy for unresectable HCC. 
Ischemic tumor necrosis is induced by occlusion of hepatic arteries with 
embolizing agents (gelantine, microspheres) together with chemotherapeutic 
drugs (Llovet and Bruix 2008). Another form of this principle is radioembolization 
(also called selective internal radiation therapy, SIRT). Here, microspheres coated 
with yttrium 90 (90Y), a β-emitting isotope, are injected intraarterially. Thereby, 
embolization as well as radiation of malignant tissue can be achieved (Sangro et 
al. 2012). 
Knowledge of molecular events taking place during tumor progression made it 
possible to develop therapies against new targets. For patients with advanced 
stage HCC systemic therapy with the multikinase inhibitor sorafenib is considered. 
It blocks Raf signalling and receptors for VEGF, PDGF, as well as c-Kit and 
thereby shows antiangiogenic and antiproliferative effects. It has been shown to 
prolong median overall survival and median time to radiologic progression, as 
compared with placebo (Llovet et al. 2008). 
2.4.1.4 Tumor microenvironment  
The tumor surrounding microenvironment largely consists of hepatic stellate cells, 
fibroblasts, immune cells, and endothelial cells. Cells within the tumor 
microenvironment influence tumor growth by multiple mechanisms. HCC is a 
highly vascularized tumor, and endothelial cells are essential for blood vessel 
formation. Activation, proliferation and migration of endothelial cells promote 
angiogenesis (Semela and Dufour 2004). Tumor infiltrating immune cells like 
lymphocytes and Kupffer cells secrete cytokines, growth factors and chemokines 
which increase cancer cell motility. Hepatic stellate cells can be detected around 
tumor sinusoids, fibrous septa and the capsule (Dubuisson et al. 2001; Faouzi et 
al. 1999; Le Bail B. et al. 1999). Activation of HSCs is not only the key event of 
hepatic fibrosis and progression to cirrhosis as a high risk factor for developing 
HCC (see chapter 2.2). Beyond that HSCs promote tumorigenesis by their ability 
to remodel the extracellular matrix. Moreover, they release different factors by 
Introduction  15 
which HCC cells become directly affected and through the activation of signalling 
pathways triggered by HSCs migratory and proliferative capability of HCC cells are 
enhanced (Amann et al. 2009a).  
2.5 Cadherins 
Cell adhesion molecules (CAM) are required to direct cells to stay at one specific 
site, to form cell-cell and cell-matrix junctions, or to disrupt these associations and 
promote directional migration. CAM can be classified into four major protein 
families: the integrin family, the selectin family, the immunoglobulin superfamily, 
and the cadherin family. 
Cadherins are characterized by conserved repeating motifs in their extracellular 
domains. The quantity of these cadherin repeats is variable. Moreover, the motif, 
which is structurally related to immunoglobulin (Ig) domains, mediates the calcium 
dependence by Ca2+ binding domains. Most cadherins are single-pass 
transmembrane glycoproteins (Angst et al. 2001).  
The cadherin superfamily can be divided into two groups, classical and 
nonclassical cadherins. Classical cadherin family was identified first and is 
important for the formation of adherens junctions between cells. Cadherins usually 
link cells by homophilic mechanism. Here, the extracellular tails of molecules of 
the same kind bind to each other. The cytoplasmic tail of classical cadherins 
mainly interacts with the actin cytoskeleton via β-catenin. Best studied protein 
members of the classical cadherin family are E-cadherin and N-cadherin. They 
play a role in mesenchymal-epithelial-transition (MET) during development and 
also in epithelial-mesenchymal-transition (EMT) during cancer metastasis 
(Peinado et al. 2004).  
A subfamily of the nonclassical cadherins is called desmosomal cadherin family, 
because of its role in the arrangement of desmosomes, like desmocollin or 
desmoglein. These cadherins interact with intermediate filaments via plakoglobin 
(Gumbiner 2005). 
Furthermore, the nonclassical cadherin group contains some cadherins which 
cannot be assigned to a specific family, called atypical cadherins, like Fat, 
Dachsous, and Flamingo. 
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2.6 FAT family 
The cadherin subfamily FAT is characterized by large extracellular domains 
containing 34 cadherin motifs, a variable number of epidermal growth factor 
(EGF)-like repeats, one or two laminin A/G domains, and a single transmembrane 
domain (Tanoue and Takeichi 2005). 
Drosophila fat was the first identified gene of this protein family (Mahoney et al. 
1991). Mutations at this gene locus caused hyperplastic overgrowth of all larval 
imaginal discs, which led to the suggestion that Fat regulates tissue growth and 
operates as a tumor suppressor protein (Bryant et al. 1988). Several studies 
revealed Fat as a member of the Hippo signaling pathway controlling cell 
proliferation and survival (Bennett and Harvey 2006). Recent studies discovered a 
role of Fat in the regulation of planar cell polarity (PCP). PCP signaling regulates 
the establishment of polarity within the plane of an epithelium and involves Fat and 
Dachsous (Sopko and McNeill 2009).  
Another Fat subfamily cadherin, Fat-like, was identified in Drosophila. It is involved 
in morphogenesis and maintenance of tubular structures of ectodermal origin and 
has no influence on growth or PCP (Castillejo-Lopez et al. 2004).  
In vertebrates Fat subfamily consists of 4 members, FAT1, -2, -3 and FAT-J (or 
FAT-4). Analysis for similarities has shown that FAT-J could be the ortholog of 
Drosophila Fat. FAT1 and FAT3 revealed highest resemblance and can form a 
subgroup together with FAT2 and Drosophila Fat-like (Tanoue and Takeichi 2005). 
Information about function of vertebrate FAT proteins is limited, only FAT1 has so 
far been studied more intensively.  
 
 
Figure 2.2 Schematic representation of the cadherin superfamily [modified from (Tanoue and 
Takeichi 2005)]. 
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2.6.1 FAT1 
Dunne et al. identified human FAT1 as the first Fat-like protein in vertebrates. 
FAT1 was shown to be expressed in a wide range of tissues (e.g. kidney, lung, 
eye, and pancreas) with higher expression in fetal opposed to adult tissue. In situ 
hybridization revealed localization of the gene encoding FAT1 on chromosome 
4q34-q35 (Dunne et al. 1995). Thereafter, FAT1 has been described in rat, mouse, 
and zebrafish (Cox et al. 2000; Down et al. 2005; Ponassi et al. 1999). Further 
studies investigated FAT1 expression in the kidney, where it is located at cell-cell 
contacts and where it forms an element of glomerular slit diaphragms (Inoue et al. 
2001). Moreover, FAT1 is found to be expressed in the Langerhans islets of the 
pancreas (Rinta-Valkama et al. 2007).  
2.6.1.1  Function, interaction and modification 
As a first step to get an insight in the function of FAT1 its gene expression has 
been silenced, but the homozygous knockout of FAT1 locus in mice was perinatal 
lethal with defects in kidney and brain (Ciani et al. 2003). Further findings 
concerned cellbiological function of FAT1. FAT1 is localized to cell-cell contacts as 
well as lamellipodia and filopodial tips, where it organizes actin filaments and 
promotes migration. Interaction of FAT1 with Enabled/vasodilator-stimulated 
phosphoproteins (Ena/VASP) is shown to be essential for regulation of actin 
dynamics and cell polarization (Moeller et al. 2004; Tanoue and Takeichi 2004). 
Ena/VASP proteins are actin-binding proteins involved in promotion and inhibition 
of actin-dependent processes and are thereby implicated in polarization and 
migration, too (Krause et al. 2003). The interaction of FAT1 with Ena/VASP 
proteins is mediated by Ena/VASP homology I (EVHI) domains, for which 
functional binding sites have been found in FAT1 (Tanoue and Takeichi 2004).  
These binding sites have also been described to bind Homer proteins (Schreiner 
et al. 2006). Homer proteins are scaffolding proteins found in many tissues, but 
are best characterized in neurons. They are implicated in many signalling 
pathways by binding different key proteins like metabotropic glutamate receptors, 
inositol trisphosphate dependent Ca2+ channels, small GTPases and others 
(Shiraishi-Yamaguchi and Furuichi 2007).  
In vascular smooth muscle cells (VSMC) FAT1 expression is upregulated in 
response to arterial injury, and knockdown of FAT1 limited migration but improved 
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proliferation (Hou et al. 2006). Further, FAT1 has been shown to interact with 
Atrophins. Atrophin proteins are conserved transcriptional repressors and their 
family includes two different members in vertebrates: Atrophin 1 (synonym 
DRPLA) and Atrophin2 (synonym RERE) (Wang and Tsai 2008). Like FAT1, 
Atrophin1 and 2 are upregulated upon injury in VSMC, but their downregulation 
has no effect on proliferation. In contrast, suppression of Atrophin 2 led to 
enhanced VSMC migration, for which FAT1 expression was essential (Hou and 
Sibinga 2009).  
Another interaction partner of FAT1 is β-catenin. Binding is accomplished by the 
acidic and prolin-rich FC domains in the FAT1 intracellular part (FAT1IC). Besides, 
expression of FAT1 affects cellular distribution and transcriptional activity of β-
catenin. Moreover, FAT1 can be spliced and the cytoplasmic domain is able to 
translocate into the nucleus due to a putative nuclear localization sequence (NLS) 
(Hou et al. 2006; Magg et al. 2005; Nishikawa et al. 2011). 
FAT1 can be modified posttranscriptionally by alternative splicing in the 
cytoplasmic domain. Thereby, two additional variants can be generated: 
FAT1(+12) (additional 12 aa in frame), FAT1(+32) (additional 32 aa in frame), and 
FAT1 (+8TR) (termination after 8aa). FAT1(+32) and FAT1 (+8TR) are specifically 
expressed within the central nervous system (CNS). In the rat kidney epithelial cell 
line NRK-52E, splicing is regulated upon cell density. Quiescent cells express 
predominantly the FAT1(+12) isoform, whereas in proliferating or migrating cells, 
respectively, a preponderance of wildtype FAT1 can be determinated, and this 
isoform is even sufficient for migration (Braun et al. 2007).  
Proteolytical cleavage is another mechanism of FAT1 modification. In HaCaT 
cells, an immortalized human keratinocyte cell line, FAT1 is processed into two 
products (p430 and p85), before achieving cell surface expression as a 
heterodimer. The cleavage is dependent on the proprotein convertase furin, and 
leads to almost complete loss of the full length p500. In melanoma cells an 
additional product, p65, has been identified, which has lost the ability to associate 
with the extracellular domain and can be found in the cytoplasm (Sadeqzadeh et 
al. 2011). 
2.6.1.2 FAT1 in cancer 
In cancer research contradictory results have been found regarding FAT1 
expression. Frequent loss of heterozygosity (LOH) of FAT1 has been described in 
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oral squamous cell carcinomas (OSCC) and astrocytic tumors (Chosdol et al. 
2009; Nakaya et al. 2007). LOH describes the deficiency of one allel of a gene in 
which the other allel was already inactivated and is mostly concerning 
tumorsuppressors. In cholangiocarcinoma immunohistochemical staining of FAT1 
demonstrated reduced expression at the normal membranous location (Settakorn 
et al. 2005). However, a study about breast cancer revealed FAT1 overexpression 
and its diffuse expression in both, carcinoma in situ and invasive carcinoma 
(Kwaepila et al. 2006). Further, FAT1 is expressed in leukemia cell lines, whereas 
in normal peripheral blood cells and in the bone marrow no expression of FAT1 
was detectible. High FAT1 expression in precursor B-cell (preB) acute 
lymphoblastic leukemia (ALL) was prognostic for shorter relapse-free and overall 
survival (de Bock et al. 2012). 
2.7 Hypoxia and hypoxia inducible factor (HIF)-1 
Oxygen is essential for most aerobic organisms. In vertebrates, O2 is necessary as 
final electron acceptor during cellular respiration. In the process of oxidative 
phosphorylation ATP is generated and O2 is reduced to water. Oxygen deficiency 
is called hypoxia and plays an important role in many pathological conditions. 
Hypoxia leads to activation of different adaption processes in the cell.  
2.7.1 The transcription factor HIF-1 
HIF-1 has been discovered as a main mediator of hypoxic adaption. Under 
hypoxic conditions, HIF-1 transcriptionally regulates expression of many target 
genes, and thereby promotes activation of required mechanisms on cellular, local, 
and systemic level (Wenger 2002). Identification of HIF-1 has been made together 
with a specific regulatory element (enhancer) of the human erythropoietin gene 
(epo) (Semenza and Wang 1992). EPO mediates production of erythrocytes and 
herewith, improves oxygen supply. Later on, it has been clarified that HIF-1 is a 
heterodimer composed of a 120 kDa HIF-1α and a 91 kDa HIF-1β subunit (Wang 
and Semenza 1995). HIF-1β, also known as aryl hydrocarbon receptor nuclear 
translocator (ARNT), is constitutively expressed and located in the nucleus, 
whereas HIF-1α is immediately degraded under normoxia. Upon hypoxic 
conditions HIF-1α is stabilized. Thus it accumulates and translocates to the 
nucleus, where it forms the dimer with HIF-1β. 
Meanwhile, two HIF-1α homologes have been identified: HIF2α and HIF3α.  
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HIF2α (EPAS) shows high sequence similarity with HIF1α, but its expression is 
more constricted. Since HIF1α is quite ubiquitinously expressed, HIF2α can only 
be found in certain tissues (Park et al. 2003). This aspect and the fact that HIF1α 
knockout embryos are non-viable (Iyer et al. 1998; Kotch et al. 1999; Ryan et al. 
1998) let infer that HIF1α is essential and cannot be replaced by its homologue.  
HIF3α (IPAS) lacks a transactivation domain, binds to HIFα subunits and has an 
antagonistic effect, which may represent a feedback regulation because HIF3α 
expression is upregulated by HIF1α in hypoxic conditions (Gu et al. 1998; Makino 
et al. 2001; Makino et al. 2007). 
 
HIF1α and HIF1β are members of the bHLH (basic helix-loop-helix)/PAS protein 
family. The bHLH domain mediates dimerization of both subunits, whereas the 
PAS domain, named after the first three proteins (PER, ARNT, SIM) in which this 
structure has been found, is important for binding to a consensus HIF DNA binding 
site (HBS) (5’-ACGTG-3’) in the so called hypoxia responsive element (HRE) 
(Jiang et al. 1996; Wang et al. 1995). Furthermore, transactivation domains (TAD) 
exist in both subunits to facilitate interaction with cofactors (CBP, p300) (Jiang et 
al. 1997). The oxygen dependency is established by two ODD (oxygen dependent 
degradation domain) in HIF1α protein (Ivan et al. 2001; Jaakkola et al. 2001).  
2.7.2 Regulation of HIF1α 
Degradation of HIF1α under normoxic conditions starts with hydroxylation of two 
proline residues in the ODD. This reaction is mediated by prolyl hydroxylases 
(PHD) and is oxygen-, iron-, 2-oxoglutarate-, and ascorbate-dependent (Kivirikko 
and Myllyharju 1998).  
Thereafter, pVHL (von Hippel-Lindau tumor suppressor) recognizes 
hydroxyproline, and hence, binds to HIF1α. pVHL is a component of the E3 
ubiquitin ligase complex. It ubiquitylates and thereby designates the protein for 
proteasomal degradation (Tanimoto et al. 2000). Furthermore, the factor inhibiting 
HIF-1 (FIH-1) hydroxylates asparagyl residues in the TAA domain of HIF1α. Thus, 
cofactors like CBP or p300 are no longer capable to bind to HIF1α (Schofield and 
Ratcliffe 2005). 
Hypoxic conditions prevent both hydroxylations, mediated by PHD as well as by 
FIH-1. Therefore, no degradation of HIF-1α takes place; it can translocate into the 
nucleus and in form of the dimer with HIF-1β promotes gene expression.  
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2.8 Aim of the thesis 
Based on the fact that to date no data regarding FAT1 in the liver exists, neither 
healthy nor pathologically changed, the aim of this thesis was to analyze 
expression and function in chronic liver disease and in hepatocellular carcinoma.  
Another focus of the analysis was regulation of FAT1 expression in HCC and the 
influence of hypoxia which was shown to be important in HCC. 
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3 Materials and Methods 
3.1 Chemicals and Reagents 
Agarose SeaKem ® LE Biozym, Hess/Oldendorf, Germany 
Agar Difco Laboratories, Augsburg 
Ampicillin Sigma-Aldrich, Deisenhofen, Germany 
β-Mercaptoethanol Sigma-Aldrich, Deisenhofen, Germany 
Ciprofloxacin Fresenius Kabi, Bad Homburg, Germany 
Collagenase type IV Sigma-Aldrich, Hamburg, Germany 
Fluconazol B. Braun, Melsungen, Germany 
DMEM medium PAA Laboratories, Cölbe, Germany 
DMSO Sigma-Aldrich, Deisenhofen, Germany 
FCS (fetal calf serum) PAN-Biotech, Aidenbach, Germany 
Milk powder Carl Roth, Karlsruhe, Germany 
Geneticin Invitrogen, Karlsruhe, Germany 
Penicillin Invitrogen, Karlsruhe, Germany 
Streptomycin Invitrogen, Karlsruhe, Germany 
Trypsin/EDTA PAA Laboratories, Cölbe, Germany 
Cycloheximid Sigma-Aldrich, Deisenhofen, Germany 
5-Azacytidine (Aza) Sigma-Aldrich, Deisenhofen, Germany 
Adenosine periodate oxidized (Adox) Sigma-Aldrich, Deisenhofen, Germany 
2,2-dipyridyl (DP) Sigma-Aldrich, Deisenhofen, Germany 
Thioacetamide (TAA) Sigma-Aldrich, Deisenhofen, Germany 
Staurosporine (STS) Alexis Biochemicals, Lausen, Switzerland 
 
3.2 Laboratory expendables 
CryoTube vials Nunc, Roskilde, Denmark 
Pipet tips 
(10, 20, 100 und 1000 µl) 
Eppendorf, Hamburg, Germany 
Falcon tubes (50 ml) Corning, New York, USA 
Glassware (various) Schott, Mainz, Germany 
Multiwell plates Corning, New York, USA 
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Pipettes (stripettes ®) 
(5, 10, 25, 50 ml) 
Corning, New York, USA 
Reaction vessels (1.5 and 2 ml) Eppendorf, Hamburg, Germany 
Strip tubes (0.2 ml) Peqlab, Erlangen , Germany 
Cell culture flasks T25, T75, T175 Corning, New York, USA 
  
 
3.3 Laboratory instruments 
Heating block: 
Thermomixer comfort Eppendorf, Hamburg, Germany 
PCR-cycler: 
GeneAmp® PCR System 9700 Applied Biosystems, Foster City, USA 
LightCycler® Real-Time PCR System Roche Diagnostics, Mannheim, 
Germany 
Pipettes: 
Eppendorf Research  
(1000 µl, 200 µl, 100 µl, 20 µl, 10 µl, 
2 µl) Eppendorf, Hamburg, Germany 
Pipette controllers: 
Accu-jet® Brand, Wertheim, Germany 
Shaking devices: 
KS 260 Basic Orbital Shaker IKA® Werke, Staufen, Germany 
Power Supplies: 
Consort E145 
Power Supply-EPS 301 
 
Peqlab, Erlangen, Germany 
Amersham Biosciences, Munich, 
Germany 
Spectrophotometer: 
EMax® Microplate Reader 
SPECTRAFluor Plus 
 
MWG Biotech, Ebersberg, Germany 
Tecan, Männedorf, Switzerland 
Scale: 
MC1 Laboratory LC 620 D Sartorius, Göttingen, Germany 
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Water bath: 
Haake W13/C10 
 
Thermo Fisher Scientific, Karlsruhe, 
Germany 
XCELLigence system: 
Real-Time Cell Analyser (RTCA) 
 
Roche Diagnostics, Mannheim, 
Germany 
Centrifuges: 
Biofuge fresco 
Megafuge 1.0 R 
 
Heraeus, Hanau, Germany 
Heraeus, Hanau, Germany 
Microscope: 
Olympus CKX41 with  
ALTRA20 soft imaging system 
 
Olympus Hamburg, Germany 
 
3.4 Buffers 
PBS buffer 140 mM NaCl  
 10 mM KCl  
 6.4 mM Na2HPO4  
 2 mM KH2PO4 pH 7.4 
    
TE buffer 10 mM Tris/HCl  
 1 mM EDTA pH 8.0 
 
3.5 Plasmids 
pBS/U6 ploxPneo by courtesy of Prof Dr. C. Deng, NIH, 
Bethesda, USA 
pcDNA3.1 Invitrogen, Karlsruhe, Germany 
pCMX Addgene, Cambridge, USA 
pIC-Cre by courtesy of Prof Dr. T. Hehlgans, 
University Regensburg, Germany 
pRL-TK Promega, Mannheim, Germany 
NFκB luc Promega, Mannheim, Germany 
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dnHIF1α by courtesy of Dr. C. Warnecke, 
Erlangen, Germany 
 
3.6 Working with bacteria 
3.6.1 Bacterial strains  
Top10 Invitrogen, Karlsruhe, Germany 
294-Cre: Cre-recombinase expressing 
Escherichia coli 
Gene Bridges, Heidelberg, Germany 
 
3.6.2 Liquid media and agar plates 
LB medium 10 g/l peptone 
 5 g/l yeast extract 
 10 g/l NaCl 
 Suspended in H2O and autoclaved  
                      For plates + 15 g/L Agar 
  For selection + 100 µg/ml Ampicillin 
 
3.6.3 Bacterial culture 
E. coli strains were cultivated on solid LB-agar as well as in liquid medium. 
Ampicillin was added to LB medium for selection of insert-containing clones after 
transformation. Bacteria were spread out on agar plates using a Drigalski spatula 
and incubated overnight at 37°C. Liquid cultures were inoculated by a single 
bacterial colony with a sterile pipette tip and grown overnight at 37°C on a shaking 
device (250 rpm). 
3.6.4 Preparation of competent cells 
Calcium chloride treatment of E.coli facilitates uptake of free plasmid DNA. 
Bacterial culture was incubated in LB medium at 37°C to an optical density (OD650) 
of 0.2-0.5.  
After incubation for 5 min on ice cells were centrifuged (1500 g, 10 min, 4°C), 
resuspended in chilled calcium chloride solution (50 mM), centrifuged and 
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resuspended again in chilled calcium chloride (50 mM). The suspension containing 
15% glycerol was aliquoted and shock frozen in liquid nitrogen for long-term 
storage. 
3.6.5 Transformation 
Chemically competent E.coli (50 µl) were thawed on ice and 100 ng plasmid DNA 
were added. After 30 min incubation on ice cells were heat shocked at 42°C for 45 
s and immediately cooled on ice. Thereafter, 250 µl pre-warmed SOC medium 
was added and the cell suspension was incubated for 1 h at 37°C with shaking. 
Then 50-150 µl of the transformation mix were plated and incubated over night at 
37°C on LB-agar containing the antibiotic necessary for selection of transformed 
cells.  
3.6.6 Isolation of plasmid DNA (mini and midi preparation) 
For mini preparation of plasmid DNA a single E.coli colony was picked and 
cultured with 3 ml LB-selection medium at 37°C over night (250 rpm).  
To obtain greater amounts of plasmid DNA 50 µl of this preculture was added to 
50 ml LB-selection medium and incubated again at 37°C over night (250 rpm). 
Then plasmids were isolated using HiSpeedTM Plasmid Midi Kit (Qiagen, Hilden, 
Germany) following the supplier’s instruction. Plasmid DNA was eluated with 
500 µl sterile H2Odest. and stored at -20°C. 
3.7 Molecular cloning 
3.7.1 Restriction digestion 
The cleavage of DNA by restriction enzymes (Roche, Mannheim, Germany) was 
performed in a volume of 20 µl with about 0.5 µg plasmid DNA, 5-10 units of 
corresponding enzyme and 2 µl of the manufacturer’s recommended reaction 
buffer. After incubation for 1 to 2 hours at the optimal reaction temperature, 
reaction was stopped by incubating for 15 min at 65°C and products are separated 
by agarose gel electrophoresis. 
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3.7.2 Dephosphorylation of plasmid DNA with alkaline phosphatase 
To prevent re-ligation of cohesive ends digested vectors were treated with shrimp 
alkaline phosphatase (SAP) to remove 5’-phosphate at 37°C for 10 min followed 
by heat-inactivation of the SAP for 15 min at 65°C.  
3.7.3 Purification of plasmid DNA by gel extraction 
The DNA vector was purified by running on an ethidium bromide containing 
agarose gel, excising the band containing the fragment under UV illumination and 
subsequent gel extraction using QIAquick Gel extraction Kit (Qiagen, Hilden, 
Germany) following the manufacturer’s instructions. 
3.7.4 Ligation 
In the presence of ATP and Mg2+ ions T4 DNA ligase is able to covalently join 
blunt or cohesive ends between a 5’-phosphate and a 3’-OH group. 
Following reaction mix was incubated for 16 h at 16°C: 
2 µl reaction buffer 
0.1-0.3 µg target vector 
0.3-1.5 µg insert DNA 
400 units T4 DNA ligase 
ad 20 µl H2Odest. 
 
3.7.5 FAT1 shRNA plasmid 
Preparation of the plasmid containing FAT1 shRNA was performed according to 
the protocol “RNAi-based conditional gene knockdown in mice using a U6 
promoter driven vector” (Shukla et al. 2007). The selected siRNA sequences 
(Table 3.1) were inserted twice as a palindrome. The U6 promoter is inactivated by 
insertion of a loxP flanked Neomycin cassette which can be deleted by Cre 
recombinase.  
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Table 3.1 Oligonucleotides for cloning of the FAT1 shRNA plasmid 
oligonucleotide sequence 
FAT1_2  
sense 
5’-GGCAGGACGTGTATGATACTCTAAAGCTTTAGAGTATCATACACGTCC
TGCCCTTTTTG-3’ 
FAT1_2  
antisense 
5’-TTAAGTTTTTCCCGTCCTGCACATACTATGAGATTTCGAAATCTCATAG
TATGTGCAGGAC-3’ 
FAT1_3  
sense 
5’-GGCACGTTACTTACCATATTGTAAAGCTTTACAATATGGTAAGTAACGT
GCCCTTTTTG-3’ 
FAT1_3  
antisense 
5’-TAAGTTTTTCCCGTGCAATGAATGGTATAACATTTCGAAATGTTATACC
ATTCATTGCACGG-3’ 
 
First, the vector was digested with ApaI restriction enzyme and overhanging ends 
were filled with Klenow enzyme. Subsequently, linearized vector was additionally 
digested with EcoRI. The insert containing siRNA sequences was prepared by 
annealing of both oligonucleotides. Thereby an overhang in form of an EcoRI 
recognition site was formed and the insert could have been ligated with the 
digested vector. After transformation and mini preparation of plasmid DNA 
restriction digestion was performed to verify integration of annealed 
oligonucleotides.  
Vectors containing the shRNA construct were then transformed into Cre-
recombinase expressing Escherichia coli (294-Cre) to delete the Neomycin 
cassette and thereby activate the promoter.  
3.8 Human tissues and tissue microarray 
Paired HCC and non-neoplastic liver tissues were obtained from HCC patients 
undergoing surgical resection. Tissue samples were immediately snap-frozen and 
stored at -80°C until subsequent analysis. A tissue microarray (TMA) of paraffin-
embedded HCC samples was constructed as described (Amann et al. 2009b). 
Clinicopathological patient characteristics are summarized in Table 4.1. 
Experimental procedures were performed according to guidelines of the charitable 
state controlled foundation HTCR (Human Tissue and Cell Research) with the 
informed patient’s consent. 
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3.9 Cell culture 
3.9.1 Cell culture medium 
DMEM (high glucose/10% 
FCS) 4.5 g/l Glucose 
 300 µg/ml L-Glutamine 
 supplemented with:  
 10% (v/v) FCS 
 400 U/ml Penicillin 
 50 µg/ml Streptomycin 
HSC medium DMEM (high glucose/10% FCS) 
 supplemented with:  
 10 µg/ml Fluconazol 
 4 µg/ml Ciprofloxacin 
Freezing medium 5 Vol 
DMEM (high glucose/10% 
FCS) 
 3 Vol FCS 
 2 Vol DMSO 
   
3.9.2 Cultivation of cell lines 
Cell culture work was always performed within a laminar flow biosafety cabinet 
(Hera Safe, Heraeus, Osterode, Germany). Cells were cultivated in a Binder series 
CB incubator (Binder, Tuttlingen, Germany) in 10% CO2 atmosphere at 37°C. For 
passaging adherent cells were washed with PBS and detached with trypsin 
(0.05%)/EDTA (0.02%) (PAA Laboratories, Cölbe, Germany) at 37°C. Trypsination 
was stopped adding DMEM containing 10% FCS. Subsequently, cells were 
centrifuged at 500 g for 5 min and the obtained cell pellet was resuspended in 
fresh culture medium and distributed to new cell culture flasks achieving a cell 
density thinning factor of 5 to 10. Medium was changed every second day. Cell 
growth and morphology were controlled and documented with a microscope 
(Olympus CKX41 with ALTRA20 Soft Imaging System, Olympus, Hamburg, 
Germany). Cell culture waste was autoclaved before disposal with a Sanoclav 
autoclave (Wolf, Geislingen, Germany).  
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3.9.3 Human hepatocellular carcinoma cell lines 
HepG2 ATCC HB-8065 
PLC ATCC CRL-8024 
Hep3B ATCC HB-8064 
 
Cell lines were obtained from the American Type Culture Collection (ATCC). 
3.9.4 Cell line of activated human hepatic stellate cells 
Activated human hepatic stellate cells have been immortalized by infection with a 
retrovirus expressing hTERT (human telomerase reverse transcriptase) (Schnabl 
et al. 2002).  
3.9.5 Isolation of primary human hepatocytes 
Primary human hepatocytes (PHH) were isolated in cooperation with the Center of 
Liver Cell Research (Department of Paediatrics and Juvenile Medicine, University 
of Regensburg, Germany) from human liver resections using a modified two-step 
EGTA/collagenase perfusion procedure (Hellerbrand et al. 2007; Hellerbrand et al. 
2008; Pahernik et al. 1996; Ryan et al. 1993; Weiss et al. 2002). Experimental 
procedures were performed according to guidelines of the charitable state 
controlled foundation HTCR (Human Tissue and Cell Research) with the informed 
patient’s consent. 
3.9.6 Isolation of human hepatic stellate cells 
Human hepatic stellate cells (HSC) were isolated in cooperation with the Center of 
Liver Cell Research (Department of Paediatrics and Juvenile Medicine, University 
of Regensburg, Germany). After perfusion and separation of hepatocytes by an 
initial centrifugation step at 50 g (5 min, 4°C) the supernatant containing the non-
parenchymal cells were centrifuged at 700 g for 7 min (4°C). The obtained cell 
pellet was resuspended in HSC medium and cells were seeded into T75 flasks. 
Within the first week, the medium was replaced daily, from the second week on 
medium change took place every 2-3 days. Under these conditions only HSC 
proliferate. Liver sinusoidal endothelial cells (LSEC) die within the first 24h. By 
cultivation on uncoated plastic HSC activate within the first 2 weeks and 
transdifferentiate to myofibroblast-like cells. Liver disease mediated HSC 
activation can be simulated in vitro that way. After 2 weeks the cell culture was 
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split 1:3 by incubating the cells with Trypsin (0.05%)/EDTA (0.02%) solution. 
Thereby, only HSC detach whereas Kupffer cells remain adherent to the plastic 
surface. Therefore, after the first passage only activated HSC remain in the cell 
culture which was confirmed by previously done analysis (Muhlbauer et al. 2006).  
3.9.7 Determination of cell number and viability 
Cell number and viability was determined by trypan blue exclusion test. The cell 
suspension was diluted 1:2 with trypan blue solution (Sigma, Deisenhofen, 
Germany) and applied on a Neubauer hemocytometer (Marienfeld GmbH, Lauda-
Königshofen, Germany). Cell with impaired cell membrane integrity are stained 
blue, and therefore, can be clearly distinguished from intact cells which appear 
white under microscopic inspection. The cell number could be calculated after 
counting cells in all four quadrants of the hemocytometer, each containing sixteen 
smaller squares, with the following equation: 
 
Cell number/ml = Z x DF x 104 ÷ 4 
Z: counted cell number 
DF: dilution factor (in the described procedure the factor is 2) 
 
The ratio of viable cells could be determined by setting the number of unstained 
cells in relation to the total cell number (blue and unstained cells). 
3.9.8 Collection of conditioned medium  
For the purpose of studying potential effects of factors secreted from activated 
HSC on HCC cells in vitro, conditioned medium (CM) from activated HSC was 
collected. 2 x 106 cells were seeded into T75 flasks, washed twice with serum-free 
DMEM, and then incubated for 24 h with serum-free DMEM (15 ml/T75). Serum-
free DMEM incubated for 24 h in cell culture flasks without cells served as control. 
Medium was then collected, centrifuged at 500 g for 10 min and the supernatant 
was stored at -80°C until use. 
3.9.9  Transient siRNA transfection 
siRNA (Table 3.2) and HiPerFect Transfection Reagent® were purchased from 
Qiagen (Hilden, Germany). 
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Table 3.2: Used siRNA and their target sequences 
name target sequence 
FAT1 siRNA1: Hs_FAT_2 CAGGACGTGTATGATACTCTA 
FAT1 siRNA2: Hs_FAT_3 CACGTTACTTACCATATTGTA 
All stars negative control siRNA not disclosed 
 
Transfection of cells was performed according to the manufacturer’s fast-forward 
siRNA transfection protocol.  
Shortly before transfection, 2 x 105 cells per well were seeded on a 6 well plate in 
2,300 µl DMEM culture medium containing 10% FCS. 150 ng siRNA per well was 
diluted in 100 µl DMEM without FCS and 12 µl of HiPerFect Transfection Reagent 
was added to the diluted siRNA and mixed. The samples were incubated for 10 
min at room temperature to allow the formation of transfection complexes which 
were then added drop-wise onto the cells. After 24 h cell medium was changed. 
Successful gene silencing was documented on the mRNA and protein levels by 
quantitative RT-PCR and Western blotting.  
3.9.10 Transient and stable plasmid transfection 
Lipofectamine method with LipofectamineTM and PLUSTM reagent (Invitrogen, 
Karlsruhe, Germany) was used to transfect cells with plasmid DNA (see 3.5). 
For transfection 2x105 cells per well were seeded on a 6 well plate. After 3 hours 
medium was changed and cells are cultivated in DMEM without FCS over night. 
On the next day medium was again changed to DMEM containing 10% FCS (1 ml 
per well) and after 3 hours cells transfection mix was added to the cells. 
Transfection mix was prepared according the manufacturer’s instructions 
containing 0.5 µg plasmid DNA per well. Cell medium was changed after 
incubation over night. 
For generation of stable transfected cell lines an expression vector containing a 
resistance gene was transfected into the cells. By addition of the antibiotic 
Geneticin® (Invitrogen, Karlsruhe, Germany) selection took place and only cells 
containing the vector with the resistance gene could survive. 
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3.9.11 NFκB reporter gene assay 
Regulatory DNA sequences can be examined by using reporter gene analysis. To 
determine the activity of a promoter, the corresponding DNA fragment containing 
the promoter region, is cloned into the reporter plasmid pGL3 basic prior to the 
firefly luciferase gene. Expression of the reporter gene is then proportional to the 
activation potential of the cloned DNA fragment. By addition of a substrate 
(luciferin) for the luciferase enzyme chemiluminescence is achieved which can be 
measured in a luminometer.  
Considering different transfection efficiencies in individual experimental assays, 
cells were cotransfected with an additional vector containing the luciferase gene 
from Renilla reniformis (pRL-TK). Chemiluminescence of Renilla luciferase was 
also measured in the luminometer and used for the normalization of the values 
depending on the transfection efficiency. Dual-Luciferase® Reporter Assay 
System (Promega, Mannheim, Germany) was used to perform luciferase assays.  
2 x 105 cells per well were seeded on a 6-well plate and transfected with 0.5 µg 
NFκB reporter construct (Promega, Mannheim, Germany) or empty control 
plasmid and pRL-TK using lipofectamin (see 3.9.10). After 24 h medium is 
removed and cells are rinsed twice with water. Subsequently, 300 µl lysis buffer 
are added per well and cells were gently shaked for 20 min at room temperature. 
Then, 50 µl of each approach were measured in the luminometer using the 
provided chemicals in the kit. 
3.10  Isolation and analysis of RNA 
3.10.1 RNA isolation and determination of RNA concentration 
RNA isolation was performed with the RNeasy® mini kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions. The principle of RNA 
isolation is based on the absorption of RNA to hydrophilic silicon-gel membranes 
in presence of suitable buffer systems. Biological samples were first lysed and 
homogenized in the presence of a highly denaturing guanidine isothiocyanate 
containing buffer, which immediately inactivates RNases to ensure isolation of 
intact RNA. To homogenize tissue samples a MICCRA D1 homogenizer (ART 
Prozess- & Labortechnik, Müllheim, Germany) was used. 
After lysis, ethanol has been added to provide ideal conditions for the binding of 
RNA to the silica-gel membranes. Contaminants have been washed away with 
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suitable buffers before RNA was eluted in water and stored at -80°C. The 
concentration of RNA was measured with the NanoDrop® ND-1000 UV/VIS 
spectrophotometer (Peqlab, Erlangen, Germany). 
3.10.2 Reverse transcription of RNA to cDNA 
Transcription of RNA to complementary DNA (cDNA) was conducted with the 
Reverse Transcription System Kit (Promega, Mannheim, Germany) which uses 
avian myeloblastosis virus reverse transcriptase (AMV-RT). The working solution 
was pipetted with contamination-free aerosol filter pipet tips after the following 
pipetting scheme: 
 0.5 µg  RNA 
 4 µl   MgCl2 (25 mM) 
 2 µl  10x reverse transcription buffer 
 2 µl  dNTP mix (10 mM) 
 1 µl  random primer 
 0.5 µl  RNasin ribonuclease inhibitor 
 0.6 µl  AMV RT 
 ad 25 µl H2Odest. 
For reverse transcription samples have been incubated in a GeneAmp® PCR 
cycler (Applied Biosystems, Foster City, USA) for 30 min at 42°C. For denaturation 
of the AMV RT the temperature has been raised to 99°C for 5 min. After cooling 
down to 4°C the obtained cDNA was diluted with 75µl H2Odest. and used 
immediately or stored at -20°C.  
3.10.3 Quantitative real time polymerase chain reaction 
To quantify the expression of specific mRNA, quantitative real time polymerase 
chain reaction (qRT-PCR) has been performed with the LightCycler® 480 System 
(Roche Diagnostics, Mannheim, Germany). The qRT-PCR is principally based on 
a conventional polymerase chain reaction (PCR), but offers the additional 
possibility of quantification, which is accomplished by fluorescence measurements 
at the end and/or during a PCR cycle. As fluorescent reagent SYBR® Green 
(SensiFAST™ SYBR No-ROX Kit, Bioline, Luckenwalde, Germany) has been 
used. SYBR® Green intercalates with double-stranded DNA whereby the 
fluorescence emission rises significantly. Therefore, the fluorescence signal 
increases proportionally with the amount of PCR products. To quantify the 
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expression of a specific gene of interest, the results have been normalized to the 
housekeeper 18s rRNA. The results were evaluated with the LightCycler® 480 
software release 1.5.0 SP4 following the manufacturer’s instructions. qRT-PCR 
was performed according following protocol: 
 2.5 µl  H2Odest. 
 
0.25 µl  forward primer (20 µM) 
 0.25 µl  reverse primer (20 µM) 
 5 µl   SYBR® Green 
Following standard scheme has been used and adapted to particular primer 
melting point temperature: 
 Initial denaturation:     95°C 2 min 
 Two step PCR (45 cycles):  95°C 5 s 
       60°C 18 s 
 Analysis of melting curve:   95°C  5 s 
       65°C 1 min 
       97°C 0 s 
For validation, after qRT-PCR PCR product has been mixed with loading buffer 
(Peqlab, Erlangen, Germany) and loaded on a agarose gel with ethidium bromide 
(50 µg/100 ml gel) to determine the PCR product length. Each experimental 
condition was performed in triplicates and experiments were repeated at least 
three times. 
 
Table 3.3 Used primers for qRT-PCR, species: mouse or human 
name forward primer reverse primer 
18s 5’ AAA CGG CTA CCA CAT CCA AG 5’ CCT CCA ATG GAT CCT CGT TA 
Coll I, human 5’ CGG CTC CTG CTC CTC TT 5’ GGG GCA GTT CTT GGT CTC 
E-Cad, human 5’-ATC CTC CGA TCT TCA ATC CCA CCA C 5’-GTA CCA CAT TCG TCA CTG CTA CGT G 
FAT1, human 5’ GTG TTT GTT CTC TGC CGT AAG 5’ TAG GCT TCT GGA TGG AGT CG 
FAT1, murine QIAGEN QuantiTect Primer Assay 
MAT2A, human 5’-CCA CGA GGC GTT CAT CGA GG 5’-AAG TCT TGT AGT CAA AAC CT 
MCP1, human 5’-CGC GAG CTA TAG AAG AAT CAC 5’-TTG GGT TGT GGA GTG AGT GT 
RANTES, human QIAGEN QuantiTect Primer Assay 
SNAIL, human QIAGEN QuantiTect Primer Assay 
TNF, human QIAGEN QuantiTect Primer Assay 
VEGF, human QIAGEN QuantiTect Primer Assay 
 
Primers were synthesized by SIGMA Genosys (Hamburg, Germany) or purchased 
as QuantiTect Primer Assays from Qiagen (Hilden, Germany). The lyophilized 
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primers (SIGMA Genosys primers) were solved in H2Odest. or TE buffer 
(QuantiTect Primer Assays), respectively, and stored at -20°C. 
3.11  Protein analysis 
3.11.1 Preparation of protein extracts 
To extract whole cell protein from cell lines cultivated in 6-well plates the cell 
culture medium was discarded and cells were washed once with PBS, then 
scraped off with a cell scraper (Corning, New York, USA) and taken up into 350 µl 
cell lysis buffer (Cell Signaling Technology, Boston, USA) supplemented with 
1 mM PMSF and a protease inhibitor cocktail (cOmplete Mini Protease Inhibitor 
Cocktail Tablets from Roche Diagnostics, Mannheim, Germany). Liver tissue 
extracts were obtained by homogenization of snap-frozen liver tissue in cell lysis 
buffer containing 1 mM PMSF and protease inhibitors using a MICCRA D1 
homogenizer (ART Prozess- & Labortechnik, Müllheim, Germany). Subsequently, 
probes were treated with an ultrasonoscope (Sonoplus hp 70, Bandelin 
electronics, Berlin, Germany) 5 x 3 s at an intensity of 70% for cell lysis. 
Subsequently, the solved proteins were separated from the non-soluble cell 
components by centrifugation at 20,000 g (15 min, 4°C). The protein solution was 
transferred into new reaction tubes and stored at -20°C.  
3.11.2 Determination of protein concentration 
To determine the protein concentrations of protein solutions the BCATM Protein 
Assay Kit (Pierce, Rockford, USA) was used. The assay combines the reduction of 
Cu2+ to Cu1+ by protein in an alkaline medium with the highly sensitive and 
selective colorimetric detection of the cuprous cation Cu1+ by bicinchoninic acid 
(BCA). The first step is the chelation of copper with protein in an alkaline 
environment to form a blue-colored complex. In this reaction, known as biuret 
reaction, peptides containing three or more amino acid residues form a colored 
chelate complex with cupric ions in an alkaline environment. One cupric ion forms 
a colored coordination complex with four to six nearby peptides bound. In the 
second step of the color development reaction, BCA, a highly sensitive and 
selective colorimetric detection reagent reacts with the cuprous cation Cu1+ that 
was formed in step 1. The purple-colored reaction product is formed by the 
chelation of two molecules of BCA with one cuprous ion. The BCA/copper complex 
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is water-soluble and exhibits a strong linear absorbance at 562 nm with increasing 
protein concentrations. 200 µl of alkaline BCA/copper(II) solution (50 parts of 
solution A mixed with 1 part of solution B) was added to 2 µl of protein solution 
using a 96-well plate and were incubated for 15 min at 37°C. Thereafter the purple 
color was measured at 562 nm with a spectrophotometer (EMax® Microplate 
Reader, MWG Biotech, Ebersberg, Germany). The optical absorbance values 
could be translated into specific protein concentrations by parallel quantification of 
a BSA standard. 
3.11.3 SDS polyacrylamid gel electrophoresis (SDS-PAGE) 
Used buffers: 
Laemmli buffer  62.5 mM Tris/HCl; pH 6.8 
    2% (w/v) SDS 
    10% (v/v) Glycerine 
    5% (v/v) β-Mercaptoethanol 
 
Running buffer  25 mM Tris/HCl; pH 8.5 
    200 mM Glycine  
    0.1% (w/v) SDS 
 
10% Resolving gel  7.9 ml  H2Odest.  
    5.0 ml  1.5 M Tris/HCl; pH 8.8 
    0.2 ml  10% (w/v) SDS 
    6.7 ml  Acrylamide/Bisacrylamid 30%/0.8% (w/v) 
    0.2 ml  Ammonium persulfate 10% (w/v) 
    0.008 ml TEMED 
 
5% Stacking gel  2.7 ml  H2Odest. 
    0.5 ml  1.0 M Tris/HCl; pH 6.8 
    0.04 ml 10% (w/v) SDS 
    0.67 ml Acrylamide/Bisacrylamid 30%/0.8% (w/v) 
    0.04 ml Ammonium persulfate 10% (w/v) 
    0.004 ml  TEMED 
For SDS-PAGE of larger proteins like FAT1 the NuPAGE® -System (Invitrogen, 
Karlsruhe, Germany) was used.  
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Gel:    NuPAGE® 3-8% Tris-Acetate Gel 1.0 mm10 well 
Buffer:   25 ml  NuPAGE® Tris-Acetate SDS Running Buffer 
    475 ml H2Odest. 
    500 µl NuPAGE® Antioxidant  
 
The protein solutions were heated at 95°C for 5 min in Laemmli buffer and applied 
on a SDS polyacrylamid gel for protein fractionation by size at 35 mA/150 V (XCell 
SureLockTM Mini-Cell, Invitrogen, Karlsruhe, Germany). As size marker HiMark™ 
Pre-Stained High Molecular Weight Protein Standard (Invitrogen, Karlsruhe 
Germany) and peqGOLD Protein-Marker V (Peqlab, Erlangen, Germany) were 
used. 
3.11.4 Western Blotting 
Used buffers: 
Standard transfer buffer  10% (v/v) Methanol 
    25 mM Tris 
    190 mM Glycine 
 
NuPAGE® transfer buffer 25 ml NuPAGE® Transfer Buffer (20x)  
50 ml Methanol 
425 ml H2Odest. 
500 µl NuPAGE® Antioxidant 
 
To detect the proteins after SDS-PAGE by use of specific antibodies proteins were 
transferred electrophoretically to a nitrocellulose membrane (Invitrogen, Karlsruhe, 
Germany) at 220 mA/300 V for 1.5 h (XCell II Blot Module, Invitrogen, Karlsruhe, 
Germany). To block unspecific binding sites, the membrane was bathed in PBS 
containing 3% BSA or 5% milk powder for 1 h at RT. Then, the membrane was 
incubated with a specific primary antibody (Table 3.4) over night at 4°C. After 
washing, the membrane was incubated with a secondary horseradish peroxidase 
(HRP) conjugated antibody (Table 3.4) for 1 h at RT. Thereafter, the membrane 
was washed and incubated with ImmunStarTM WesternCTM Kit (BioRad, München, 
Germany) for 3 min. This system utilizes chemiluminescence technology which 
was detected by the ChemiDoc XRS (BioRad, München, Germany) imaging 
system.  
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Table 3.4 Used primary and secondary antibodies for Western Blot analysis 
Primary antibody Dilution 
rabbit anti-FAT1 (Atlas Antibodies AB, Stockholm, Sweden) 1:1000 
rabbit anti-collagen I (Rockland, Gilbertsville, PA, USA) 1:5000 
mouse anti-α-sma (Abcam, Cambridge, UK) 1:500 
rabbit anti-IκBα (Cell Signaling, Beverly, MA, USA) 1:1000 
mouse anti-β-actin (Sigma-Aldrich, Deisenhofen, Germany) 1:20,000 
mouse anti-α-Tubulin (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 1:200 
mouse anti-HIF1α (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 1:200 
Secondary antibody  
anti-mouse HRP (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 1:3000 
anti-rabbit HRP (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 1:3000 
 
3.11.5 Quantification of caspase-3/7 activity 
Caspases, or cysteine-aspartic acid proteases, are a family of cysteine proteases, 
which play essential roles in apoptosis. There are two types of apoptotic caspases: 
initiator (apical) caspases and effector (executioner) caspases. Initiator caspases 
(e.g. caspase-2, -8, -9, -10) cleave inactive pro-forms of effector caspases, 
thereby activating them. Effector caspases (e.g. caspase-3, -6, -7) in turn cleave 
other protein substrates within the cell, to trigger the apoptotic process. To analyze 
caspase-3/7 activity we used the Apo-One Homogeneous Caspase-3/7 Assay Kit 
(Promega, Mannheim, Germany) according to the manufacturer’s instructions. We 
used 6000 cells/well (96-well plate) and incubated cells with the provided caspase 
substrate Z-DEVD-R110 for 1h. Cleavage of the non-fluorescent caspase 
substrate Z-DEVD-R110 by caspase-3/7 liberates the fluorescent rhodamine 110, 
which was detected fluoro-spectrometrically with a SPECTRAFluor Plus 
microplate reader (Tecan, Männedorf, Switzerland) at wavelengths of 485 nm 
(excitation) and 520 nm (emission). Each experimental condition was performed in 
triplicates and experiments were repeated at least twice. 
3.11.6 S-Adenosylmethionine (SAM) extraction and analysis 
For analysis of S-Adenosylmethionine (SAM) in cell culture medium, cells were 
cultured in serum free medium for 24 h. Subsequently, medium was collected, 
centrifuged, and the supernatant was snap-frozen and stored at -80°C. Further, 
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cell number in corresponding cell culture plates was determined by counting the 
trypsinized cells. 
Samples were further processed by the Institute of Functional Genomics, 
University of Regensburg. Briefly, cell culture medium was spiked with stable 
isotope-labeled standards, dried by means of an infrared evaporator, and the 
residues were reconstituted in 0.1 mol/L acetic acid.  
Liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-
ESI-MS/MS) was performed as described (Stevens et al. 2010). 
3.12  Flow cytometry 
3.12.1 Annexin V / Propidium iodide double staining 
At early stages of apoptosis cells change the structure of their membrane, which 
leads to the exposure of phosphatidylserine on the membrane surface. In living 
cells, phosphatidylserine is transported to the inside of the lipid bilayer by the 
aminophospholipid translocase, a Mg2+ ATP dependent enzyme. At the onset of 
apoptosis, phosphatidylserine is translocated to the external membrane and 
serves as a recognition signal for phagocytes.  
Annexins are ubiquitous homologous proteins that bind phospholipids in the 
presence of calcium. Since the redistribution of phosphatidylserine from the 
internal to the external membrane surface represents an early indicator of 
apoptosis, Annexin V and its conjugates can be used for the detection of apoptosis 
because they interact strongly and specifically with exposed phosphatidylserine.  
The differentiation between apoptotic and necrotic cells can be performed by 
simultaneous staining with propidium iodide (PI), a dye that stains by intercalating 
into nucleic acid molecules. The cell membrane integrity excludes PI in viable 
cells, whereas necrotic cells are permeable to PI. Thus, dual parameter flow 
cytometric analysis allows for the discrimination between viable, early apoptotic 
and late apoptotic/necrotic cells.  
To quantify apoptotic cells we used the Annexin V-FITC Detection Kit (PromoKine, 
Heidelberg, Germany). Therefore, we resuspended 2 x 105 cells in 500 µl of the 
provided binding buffer and added 5 µl of the FITC-labeled Annexin V reagent and 
5 µl of PI solution. After incubation for 5 min at room temperature in the dark flow 
cytometric analysis was performed. The FITC-Annexin V signal was detected at a 
wavelength of 525 ± 12.5 nm, the PI signal at a wavelength of 620 ± 12.5 nm. The 
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result of the dual parameter flow cytometric analysis were depicted as dotplot and 
evaluated by quadrant analysis. The y-axis of the dotplot shows PI fluorescent 
signal intensity, the x-axis FITC-Annexin V fluorescent signal intensity. 
Discrimination of viable, early apoptotic and late apoptotic/necrotic cells were done 
by means of different intensities of FITC-Annexin V of PI fluorescent signals. 
Viable cells show low FITC-Annexin V and PI fluorescence (lower left quadrant), 
early apoptotic cells show high FITC-Annexin V but low PI fluorescence (lower 
right quadrant) and late apoptotic/necrotic cells show both high FITC-Annexin V 
and PI fluorescence (upper right quadrant). 
To asses the effects of a specific apoptosis or necrosis inducing reagent the 
percental distribution of viable, early apoptotic and late apoptotic/necrotic cells 
related to the total of counted cell (104 cells) were calculated. 
3.13  Functional assays 
3.13.1 XTT 
Cell proliferation was quantified with the XTT kit (Roche Diagnostics, Mannheim, 
Germany). The assay is based on the ability of metabolic active cells to reduce the 
tetrazolium salt XTT (2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-
[phenylamino)carbonyl]-2H-tetrazolium hydroxide) to orange colored compounds 
of formazan. The dye formed is water soluble and dye intensity can be read with a 
spectrophotometer at a wavelength of 450 nm and a reference absorbance 
wavelength of 650 nm. The intensity of the dye is proportional to the number of 
metabolic active cells.  
To quantify the effects of siRNA treatment on cell proliferation, cells were seeded 
in 96-well tissue culture plates (4000 cells per well) and incubated for different time 
intervals. At the chosen time points XTT reagent was added and the intensity of 
the forming dye was measured two hours later with an EMax Microplate Reader 
(MWG Biotech, Ebersberg, Germany). Values of optical density (OD) at individual 
time points were corrected for background by subtracting the OD value of blank 
wells without cells. Each experimental condition was performed in triplicate and 
experiments were repeated three times. 
Materials and Methods  42 
3.13.2 Attachment and proliferation assay (xCELLigence System, 
Roche) 
By the use of so-called E-plates it is possible to examine attachment and 
proliferation of cells in the xCELLigence System from Roche (Penzberg, 
Germany). Each well on ePlates contains a sensor with two microelectrodes which 
measures the resistance between two electrodes on the bottom of the well. This 
value correlates with the number of cells and is transmitted in real time as a 
change in cell index on the connected laptop. The more cells settle to the well 
bottom, the higher the resistance, and thus the cell index. ePlates were coated at 
the beginning of the experiment with 100 µl DMEM with FCS and equilibrated for 
30 minutes at room temperature. 2000 cells/100 µl DMEM with FCS were added 
after the measurement of background resistance. Following incubation for 10 
minutes at room temperature ePlate was inserted into the analyzer. Data was 
evaluated with the appropriate software.  
3.13.3 Migration (96-well) 
The migratory potential of cells was quantified using the Cultrex 96 Well Cell 
Migration Assay (Trevigen, Gaithersburg, USA) according to the manufacturer’s 
instructions. This assay is based on two medium-filled compartments separated by 
a microporous membrane. In general, cells are placed in the upper compartment 
and are allowed to migrate through the pores of the membrane to the lower 
compartment, in which chemotactic agents are present. After an appropriate 
incubation time, migrated cells are detached from the lower side of the membrane 
by a detachment buffer and quantified using calcein acetoxymethylester (calcein 
AM). Calcein AM is internalized by the cells, and intracellular esterases cleave the 
acetomethylester moiety to generate free calcein, which can be detected 
fluorometrically.  
Cells were seeded into the upper compartment of the provided 96-well plate 
(4x104 cells/well) in DMEM. The lower compartment was filled with DMEM 
supplemented with conditioned medium from fibroblasts and 10% FCS as 
chemoattractants. After incubation at 37°C for 5 h cell migration was quantified by 
fluorimetry using a SPECTRAFluor Plus microplate reader (Tecan, Männedorf, 
Switzerland). Each experimental condition was performed in triplicates and 
experiments were repeated twice.  
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3.13.4 Migration (xCELLigence System, Roche) 
In contrast to the above-mentioned migration assay which only allows endpoint 
analysis, the xCELLigence System allows to observe behavior of the cells in real 
time.  
The lower compartment of so called CIM plates was filled with 160 µl conditioned 
medium from fibroblasts. After assembly with the upper part 27 µl DMEM without 
FCS was given on the membrane and CIM plate was equilibrated for 1 hour at 
37°C. 4x104 cells /100 µl DMEM without FCS were added following the 
measurement of background resistance. After incubation for 30 minutes at room 
temperature ePlate was inserted into the analyzer. Data was evaluated with the 
appropriate software.  
3.14  Animal experiments 
Animals were purchased at Charles River Laboratories (Sulzfeld, Germany) and 
housed in a 22°C controlled room under a 12 h light-dark cycle with free access to 
food and water. After one week of acclimatization mice were used for different 
experimental settings. 
3.14.1 Bile duct ligation 
Experimental cholestasis induced by bile duct ligation (BDL) is a commonly used 
model of liver injury. BDL or sham surgeries were performed in 4 female C57Bl/6 
mice each as described (Gabele et al. 2009). After midline laparotomy the 
common bile duct was exposed and ligated. Then, the abdomen was closed again 
in layers. After 3 weeks, blood and livers were collected for further analysis.  
3.14.2 Thioacetamid induced liver fibrosis 
Thioacetamide (TAA) is a hepatotoxin, which induces liver fibrosis by injury. It is a 
commonly used chemically induced model of fibrosis (Brodehl 1961).  
TAA induced liver fibrosis was caused in female C57Bl/6 by administering TAA at 
a dose of 300 mg/L in drinking water for 14 weeks. 
3.14.3 Experimental NASH model 
Male BALB/c mice were purchased at 6 weeks of age, divided into two groups 
(n=5 each) and fed either with control diet or a non-alcoholic steatohepatitis 
(NASH) inducing high fat diet containing 30% lard, 1.25% cholesterol and 0.5% 
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sodium cholate (Matsuzawa et al. 2007). After 30 weeks feeding animals were 
sacrificed and liver tissue was immediately frozen. 
3.14.4 Tumor cell inoculation and measurement of tumor growth 
in NMRI (nu/nu) mice 
To analyze tumor growth in vivo tumor cells were injected subcutaneously into 
immunodeficient NMRI (nu/nu) mice. This experiment was performed in 
cooperation with Dr. Thilo Spruss (animal care facility, University of Regensburg). 
Mice were housed in a 22°C controlled room under a 12 h light-dark cycle with free 
access to food and water in the central animal laboratories. 
Cells were harvested after incubation with PBS containing 0.05% trypsin and 
0.04% ethylenediaminetetraacetic acid (Sigma-Aldrich, Steinheim, Germany). 
Tumor cells were washed twice with serum-free Dulbecco’s modified Eagle’s 
medium at room temperature and were resuspended in Dulbecco’s modified 
Eagle’s medium at a concentration of 5 x 106 cells/ml. For each of the cell lines, a 
group of 10 NMRI (nu/nu) mice with a mean body weight of 32 g was formed. All 
mice were injected subcutaneously with a cell suspension of 0.1 ml containing 5 x 
105 cells of a single line. Tumor growth kinetics were recorded by weekly 
measurement of tumor diameters at the inoculation site (region of the thoracic 
mammary fat pad) with an electronic caliper. Tumor areas were calculated as the 
product of two perpendicular diameters, one measured across the greatest width 
of the tumor. For ethical reasons, mice were sacrificed at day 21 after the first 
tumors underwent ulceration, and the tumors were taken out and stored for 
subsequent analysis. 
3.15  Histology and Immunohistochemistry 
For histological and immunohistochemical analysis tissue was fixed for 24 hours in 
buffered formaldehyde solution (3.7% in PBS) at room temperature, dehydrated by 
graded ethanol and embedded in paraffin. Sections were cut at 5 µm and stuck on 
glass slides.  
3.15.1 Hematoxylin/Eosin staining 
Paraffin embedded tissue sections stuck on a glass slide were deparaffinized with 
xylene. Then, the tissue was rehydrated and dipped into an aequeous solution of 
hematoxylin. Hematoxylin binds to basophilic structures such as the anionic 
Materials and Methods  45 
phosphate groups of nucleic acids. Following dehydration in alcohol, the tissue 
was dipped into an alcoholic solution of eosin. Eosin carries a negative charge and 
reacts with cationic groups common to amino acids (eosinophilic structures). Once 
stained, the tissue was covered with a thin glass cover slip (Carl Roth, Karlsruhe, 
Germany) attached by mounting medium (Vector Laboratories, Burlingame, USA). 
In general, the eosin imparts a pink to red color to proteins, and hematoxylin stains 
the basophilic structures, usually containing nucleic acids, such as ribosomes and 
the chromatin-rich cell nucleus, from blue to purple. Digital images were captured 
with an Olympus CKX41 microscope equipped with the ALTRA20 Soft Imaging 
System (Olympus, Hamburg, Germany). 
3.15.2 Immunohistochemical analysis of FAT1 and Ki67 
For visualization of FAT1 and Ki67 positive cells the LSAB+ System HRP-Kit 
(Dako, Hamburg, Germany) was used according to the manufacturer’s 
instructions. The technique used in this kit is based on the LSAB (labelled 
streptavidin biotin) method.  
 
Used buffer: 
TBS-T buffer   6.1 g/L Tris 
    8.8 g/L NaCl 
    37 ml  1 N HCl 
    ad 1L  H2Odest. pH 7.6 
    0.05%  TWEEN 20 
 
Table 3.5 Used antibodies for immunohistochemical staining 
Antibody Dilution (in TBS + 1%BSA) 
rabbit anti-FAT1 (Atlas Antibodies AB, Stockholm, Sweden) 1:50 
rabbit anti-Ki67 (Abcam, Cambridge, UK) 1:50 
 
Deparaffinated and rehydrated tissue sections on glass slides were incubated for 5 
min in 3% H2O2 to quench endogenous peroxidase activity. Subsequently, tissue 
was incubated for 30 minutes with a primary antibody (Table 3.5) at RT in a humid 
chamber. After washing in TBS-T buffer, sequential incubations with the 
biotinylated link antibody (15 min) and peroxidase-labeled streptavidin (15 min) 
were performed. Staining is completed after incubation with the provided 
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substrate-chromogen (3,3’-diaminobenzidine) solution (5 min). Tissue was then 
counterstained in an aqueous solution of hematoxylin for 1 min, rinsed with 
H2Odest. and covered with a thin glass cover slip (Carl Roth, Karlsruhe, Germany) 
attached by mounting medium (Vector Laboratories, Burlingame, USA). Digital 
images were captured with an Olympus CKX41 microscope equipped with the 
ALTRA20 Soft Imaging System (Olympus, Hamburg, Germany). 
3.15.3 TUNEL staining (TdT-mediated dUTP-biotin nick end 
labeling) 
Tissue sections of nude mice tumors were stained for apoptotic cells with the 
DeadEnd Fluorometric TUNEL System (Promega, Mannheim, Germany) 
according to the manufacturer’s instructions. Thereby, free DNA ends, which are 
characteristic for apoptotic cells, are marked with Fluorescein-12-UTP by terminal 
desoxynucleotidyl transferase (TdT) and can be made visible, in this way. Nuclear 
staining was performed with DAPI (Hard Set Mounting Medium with DAPI, H-1500, 
Vectashield, Vector Laboratories, Burlingame, USA) and fluorescence was 
analyzed with a fluorescence microscope.  
3.16  Statistical analysis 
Values are presented as mean ± SEM or mean ± SD as indicated. All experiments 
were repeated at least three times. Comparison between groups was made using 
the Student’s unpaired t-test. A p-value < 0.05 was considered statistically 
significant. Contingency table analysis and the two-sided Fisher’s exact test were 
used to study the statistical association between clinicopathological and 
immunohistochemical variables. Calculations were performed using the statistical 
computer package GraphPad Prism (GraphPad Software, San Diego, CA, USA) or 
SPSS (SPSS, Chicago, IL, USA). 
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4 Results 
As described in the introduction FAT1 is involved in different pathological 
circumstances, however, with regards to the role of FAT1 in liver cells or liver 
disease respectively, no data are available at present. The aim of this thesis was 
to address this issue. 
 
In particular, the focus was placed on two aspects: 
4.1 Expression and function of FAT1 in liver fibrosis 
4.2 Expression and function of FAT1 in hepatocellular carcinoma 
 
4.1 Expression and function of FAT1 in chronic liver disease 
4.1.1 FAT1 expression in non-alcoholic fatty liver disease (NAFLD) 
To investigate the role of FAT1 in chronic liver disease, we first analyzed FAT1 
expression in a murine dietary NASH model. Thereto, mice received a non-
alcoholic steatohepatitis (NASH) inducing high fat diet or were fed with standard 
chow for 30 weeks.  
Hepatic FAT1 expression was significantly higher after feeding a NASH 
inducing diet compared to mice fed with standard chow (Figure 4.1). 
 
 
Figure 4.1 Analysis of FAT1 mRNA expression in the dietary murine NASH model (NASH, n=5) 
and control mice (ctrl, n=5). *p<0.05 compared to control. 
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In human NASH FAT1 expression revealed a high variation but significantly 
correlated (r=0.64, p=0.002) with the expression of collagen alpha I(1), the most 
abundant extracellular matrix protein of fibrotic liver tissue. In contrast, no 
significant correlation was found between the expression of FAT1 and tumor 
necrosis factor (TNF), a proinflammatory cytokine which is significantly elevated 
during liver inflammation (Figure 4.2). 
 
                  
 
Figure 4.2 Correlation of FAT1 with collagen alpha I(1) (Coll I) (left panel) and tumor necrosis 
factor (TNF) mRNA expression (right panel) in hepatic tissues of patients with non-alcoholic fatty 
liver disease (n=20). 
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4.1.2 FAT1 expression in chronic liver disease 
We further analyzed FAT1 expression in murine models of hepatic fibrosis. 
Experimental cholestasis induced by bile duct ligation (BDL) is a commonly 
used model to induce liver fibrosis (Iredale 2007). Three weeks after BDL, we 
analyzed FAT1 expression by qRT-PCR and found significant upregulation of 
FAT1 in response to BDL compared to sham treated mice (Figure 4.3). 
 
 
Figure 4.3 Analysis of FAT1 mRNA expression in bile-duct ligated (BDL, n=4) and sham-treated 
(sham, n=4) mice. *p<0.05 compared to sham. 
 
Another model to induce liver fibrosis is iterative treatment with hepatotoxic 
agents. One of these is thioacetamide (TAA). FAT1 expression was enhanced in 
mice treated with TAA for 14 weeks compared to control mice (Figure 4.4).  
 
 
Figure 4.4 Analysis of FAT1 mRNA expression in TAA treated (TAA, n=3) and control (ctrl, n=3) 
mice. *p<0.05 compared to control. 
Also in cirrhotic human liver tissue of patients with alcoholic liver disease and 
chronic viral hepatitis B or C infection FAT1 expression was significantly higher 
compared to normal human liver tissue (Figure 4.5). 
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Figure 4.5 FAT1 mRNA expression in cirrhotic human liver tissue (n=6) compared to normal liver 
tissue (n=7). *p<0.05 compared to normal. 
 
Immunohistochemistry revealed no significant differences in the staining 
intensity between normal and cirrhotic liver tissue. However, myofibroblast like 
cells in the fibrotic septa revealed a significant immunosignal (Figure 4.6).  
 
 
Figure 4.6 Immunohistochemical analysis of FAT1 in normal (panel I, III) and cirrhotic liver tissue 
(panel II and IV). Myofibroblast like cells in fibrotic septa revealed a strong FAT1 immunosignal (IV, 
black arrows). 
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4.1.3 Expression of FAT1 in hepatic stellate cells (HSCs) 
These data indicated activated HSCs as cellular source of enhanced FAT1 
expression. Therefore, we determined the expression of FAT1 during the course of 
in vitro activation of human HSCs by quantitative RT-PCR (Figure 4.7). There is a 
significant increase of FAT1 mRNA expression during activation of HSCs.  
We confirmed FAT1 upregulation during activation of HSCs on protein level 
(Figure 4.8). In parallel to FAT1, we determined Coll I and α-sma to document the 
activation of HSCs during in vitro culture. 
 
 
Figure 4.7 Analysis of FAT1 mRNA during in vitro activation of human HSCs. Freshly isolated 
HSCs were cultured on plastic and RNA was isolated after different times of culture (day 2, 7 and 
10). 
 
 
 
Figure 4.8 FAT1 protein expression during in vitro activation of human HSCs. Collagen alpha I(1) 
(Coll I) and alpha-smooth muscle actin (α-sma) were used as activation markers. Ponceau S 
staining of the same membrane was used to demonstrate equal protein loading. 
 
4.1.4 Functional role of FAT1 in activated HSCs 
To gain insight into the functional role of increased FAT1 in activated HSCs, FAT1 
was suppressed by transfection with specific siRNA. Quantitative RT-PCR 
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analysis revealed a strong suppression of FAT1 mRNA expression in transfected 
primary HSCs in contrast to control transfected cells. Downregulation of FAT1 
expression was confirmed on protein level by Western blot analysis (Figure 4.9). 
 
 
Figure 4.9 Analysis of FAT1 mRNA and protein in untransfected cells (ctrl), in control siRNA (ctrl 
siRNA), and FAT1 siRNA (FAT1 si#2, FAT1 si#3) transfected cells. β-actin served as housekeeper 
for Western Blot analysis. 
 
Morphology did not differ between cells (Figure 4.10), but expression analysis 
revealed lower levels of the proinflammatory genes MCP1 and RANTES in FAT1 
suppressed HSCs (Figure 4.11). 
 
 
Figure 4.10 Morphology of untransfected cells (ctrl), control siRNA (ctrl siRNA), and FAT1 siRNA 
(FAT1 si#2, FAT1 si#3) transfected cells (magnification 40x).  
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Figure 4.11 Effect of FAT1 suppression on expression of the inflammatory genes MCP1 and 
RANTES. *p<0.05 compared to control siRNA. 
 
Both cytokines are regulated by NFκB, which plays a key role in regulating 
immune responses and cell survival. A decrease of NFκB activity is mainly 
considered as having anti-inflammatory and pro-apoptotic effects. The inactive 
form of NFκB is bound in the cytoplasm to IκBα and regulation of NFκB activity is 
mediated by phosphorylation, ubiquitinylation and subsequent degradation of IκBα. 
Consequently, NFκB is free and can translocate to the nucleus, where it binds to 
and activates the promoter of NFκB-dependent genes. 
To analyze the activity of the NFκB pathway we performed Western blotting for 
IκBα. We could detect more IκBα in HSCs transfected with siRNA against FAT1. 
This indicates a reduced NFκB activity in FAT1 suppressed HSCs (Figure 4.12).  
 
 
Figure 4.12 Western Blot analysis for IκBα and α-tubulin (housekeeper) in FAT1 suppressed cells 
and control cells.  
 
Accordingly, an NFκB reporter gene assay confirmed reduced NFκB activity in 
FAT1 suppressed HSCs (Figure 4.13).  
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Figure 4.13 Reporter gene assay for NFκB activity in FAT1 suppressed (FAT1 si#2, FAT1 si#3) 
and control cells (ctrl siRNA). *p<0.05 compared to control siRNA.. 
 
In addition to its effect on proinflammatory gene expression NFκB has been shown 
to be critical for apoptosis resistance of activated HSCs (Hellerbrand et al. 1998; 
Oakley et al. 2005). 
To investigate a functional role of FAT1 in apoptosis of HSCs we analyzed 
caspase-3/7 activity, which plays a key role in the cell death program. Caspase-
3/7 activity was higher in staurosporine (STS) induced apoptotic cells after 
suppression of FAT1 compared to control cells (Figure 4.14). 
 
 
 
Figure 4.14 Analysis of caspase-3/7 activity in FAT1 suppressed and control HSCs after STS 
(500 nM; 4h) induced apoptosis. *p<0.05 compared to control siRNA. 
 
In line with this, Annexin V and propidium iodide (PI) double staining and following 
FACS analysis of HSCs revealed higher STS-induced apoptosis rate of FAT1 
suppressed cells compared to control cells (Figure 4.15).  
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Figure 4.15 Assessment of STS-induced (500 nM, 4h) apoptosis by flow cytometry applying 
annexin V and propidium iodide (PI) staining. Depicted is the mean-percentage of total apoptotic 
cells from 3 independent experiments. *p<0.05 compared to control siRNA. 
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4.2 Expression and function of FAT1 in HCC 
4.2.1 Expression of FAT1 in HCC cell lines and primary hepatocytes 
First, the expression of FAT1 was analyzed in three different HCC cell lines 
(Hep3B, HepG2, and PLC) compared to primary human hepatocytes (PHH). 
Quantitative RT-PCR analysis showed an upregulation of FAT1 expression in 
HCC cells compared to PHH. HepG2 cells demonstrate highest FAT1 mRNA 
levels within the HCC cell lines, Hep3B and PLC display similar FAT1 expression 
(Figure 4.16).  
 
 
Figure 4.16 qPCR analysis of FAT1 mRNA in HCC cell lines (Hep3B, HepG2, PLC) and primary 
human hepatocytes (PHH). 
 
To verify these results, we analyzed FAT1 protein expression in these cells by 
Western blotting. Thereby, overexpression of FAT1 in HCC cell lines compared to 
primary hepatocytes was shown (Figure 4.17). 
 
 
Figure 4.17 Western Blot analysis for FAT1 protein and β-actin in HCC cell lines (Hep3B, HepG2, 
PLC) and PHH. 
 
To evaluate whether this result can be confirmed in vivo we next examined FAT1 
expression in tumor tissues of 14 HCC patients compared to corresponding non-
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neoplastic liver tissues. Similarly, quantitative RT-PCR revealed a significant 
upregulation of FAT1 expression in cancerous tissue (Figure 4.18).  
 
Figure 4.18 FAT1 mRNA expression in tumor tissue (T) and corresponding non-tumorous tissue 
(N). *p<0.05 compared to N.  
 
To further evaluate the functional effects of FAT1 upregulation in HCC in vivo, we 
analyzed FAT1 protein expression in a series of 112 human HCC tissues, applying 
TMA technology. Membranous FAT1 staining intensity varied significantly in 
individual patients. For descriptive data analysis, HCC were separated into tissues 
with strong and weak immunosignal (representative examples are depicted in 
Figure 4.19), and immunohistochemical results were correlated with 
clinicopathological tumor characteristics (Table 3.1). 
 
 
Figure 4.19 Immunohistochemical staining of FAT1 in HCC tissues with strong (right panel) and 
weak (left panel) membranous staining (magnification 100x). 
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A strong membranous FAT1 staining was significantly associated with higher 
tumor stage (p=0.042) and a higher proliferation index (Ki67 staining; p=0.040). No 
correlation was found between FAT1 expression and tumor staging, age, sex, or 
tumor size.  
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Table 4.1 FAT1 immunoreactivity (IR) in HCC-tissues of 112 patients in relation to 
clinicopathological characteristics and proliferation rate. 
Variable     
  
  FAT1 IR FAT1 IR 
p* 
  Categorization n %   negative positive 
    
 
     
Clinico-pathological characteristics 
     
  
  
 
     
Age at diagnosis        
  <60 years 40 35,7  13 27 1.000 
  ≥60 years 72 64,3  23 49  
        Gender        
  female 17 15,2  3 14 0.259 
  male 95 84,8  33 62  
       Tumor stage       
  pT1 42 37,5  17 25 0.042 
  pT2 27 24,1  12 15  
  pT3 38 33,9  6 32  
  pT4 3 2,7  1 2  
  nd 2 1,8  0 2  
       Histological grade       
  G1 42 37,5  14 28 1.000 
  G2 59 52,7  19 40  
  G3 11 9,8  3 8  
       Tumor size         
  ≤ 5 cm 60 53,6  19 41 0.921 
  > 5 cm 36 32,1  11 25  
  nd 16 14,3  6 10  
        Cirrhosis        
  no 31 27,7  13 18 0.246 
  yes 77 68,7  23 54  
  nd 4 3,6  0 4  
  
  
 
    
Proliferation rate (MIB1-Index)      
  ≤ 5% 46 41,1  20 26 0.040 
  > 5% 66 58,9  16 50  
     
 
    
* Fisher's exact test (2-sided); bold face representing p-values <0.05. 
(nd: no data available; IR: immunoreactivity)  
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4.2.2 Functional role of FAT1 in HCC cells 
4.2.2.1 Suppression of FAT1 by siRNA transfection 
To gain insight into the functional role of increased FAT1 in HCC cell lines, FAT1 
was suppressed by transient transfection with specific siRNA. Quantitative RT-
PCR analysis revealed a strong suppression of FAT1 mRNA expression in 
transfected cell lines after 3d, whereas no change of FAT1 expression was seen 
on protein level. It lasted as far as day 8 until a downregulation of FAT1 expression 
on protein level was achieved (Figure 4.20). 
 
 
 
Figure 4.20 Analysis of FAT1 in control cells (ctrl), control siRNA (ctrl siRNA) and FAT1 siRNA 
(FAT1 si#2, FAT1 si#3) transfected HCC cells by qRT-PCR and Western Blot 3d (upper panel) and 
8d (lower panel) after transfection. *p<0.05 compared to control siRNA. 
 
These data indicated a high protein stability of FAT1. To further clarify this result 
protein synthesis was inhibited by cycloheximide (Cyclo). Subsequent Western 
Blot analysis showed that FAT1 protein expression can be detected until 48 h after 
blocking protein synthesis in HCC cells, and that confirmed a long half life of FAT1 
protein (Figure 4.21). 
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Figure 4.21 FAT1 protein analysis in HCC cell lines at different time points after stimulation with 
cycloheximide (Cyclo; 50 µg/ml). 
 
4.2.2.2 Stable transfected cell clones 
Since it required repeated and longtime (transient) transfection with siRNA to 
reach sufficient suppression of FAT1 (see 4.2.2.1) we prepared stable suppressed 
HCC cell clones. As a further advantage stably transfected cells allow the use for 
in vivo studies (see 4.2.3). 
FAT1 was suppressed by stable transfection with a shRNA expressing vector 
containing the sequence of FAT1 siRNA (clone 1 and 2). The vector without an 
insert was used as a control (mock). Quantitative RT-PCR analysis revealed a 
suppression of FAT1 mRNA expression in the cell clones (FAT1 shRNA#1, FAT1 
shRNA#2). Downregulation of FAT1 expression in the cell clones was confirmed 
on protein level by western blot (Figure 4.22).  
 
           
Figure 4.22 FAT1 mRNA (left panel) and protein (right panel) expression in stable transfected cell 
clones (FAT1 shRNA#1, FAT1 shRNA#2) and mock transfected controls (ctrl). *p<0.05 compared 
to control. 
 
Cell morphology did not differ between mock transfected controls and stable FAT1 
suppressed HCC cells (Figure 4.23). 
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Figure 4.23 Morphology of mock-transfected cells (ctrl) and FAT1 shRNA (FAT1 sh#1, FAT1 sh#2) 
transfected cells (magnification 40x). 
 
Further, expression of markers for cell differentiation E-Cadherin and Snail were 
not influenced by FAT1 suppression (Figure 4.24). 
 
 
 
Figure 4.24 E-Cadherin (E-Cad) and Snail mRNA expression in FAT1 suppressed cells (FAT1 
shRNA#1, FAT1 shRNA#2) and control cells.  
4.2.2.3 Functional changes upon stable transfection 
To ascertain the functional role of FAT1 in HCC, we performed functional in vitro 
assays with stable FAT1 suppressed cells.  
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HCC cells with stable suppressed FAT1 expression showed a prolonged doubling 
time (Figure 4.25).  
 
Figure 4.25 Doubling time of stable transfected cell clones (FAT1 shRNA#1, FAT1 shRNA#2) and 
control cells. *p<0.05 compared to control. 
 
Next, we analyzed whether FAT1 suppression affects the migratory potential of 
HCC cells. Therefore, the Cultrex cell migration assay and the ROCHE RTCA 
XCELLigence system were used (see also chapters 3.13.3 and 3.13.4) and a short 
time span of 5 h was chosen to exclude anti-proliferative effects of FAT1 
suppression. Noteworthy, we observed a significant inhibition of cell migration after 
suppression of FAT1 (Figure 4.26). 
 
 
Figure 4.26 Migration analysis of stable FAT1 suppressed HCC cells (FAT1 shRNA#1, FAT1 
shRNA#2) and mock transfected control cells. *p<0.05 compared to control. 
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We further investigated the effect of stable FAT1 suppression on apoptosis in HCC 
cells after serum starvation for 48 h. Notably, Annexin V and propidium iodide (PI) 
double staining and following FACS analysis revealed a higher apoptosis rate in 
cells with suppressed FAT1 expression compared to control cells (Figure 4.27). 
 
 
Figure 4.27 Assessment of apoptosis by flow cytometry applying annexin V and propidium iodide 
(PI) staining. Depicted is the mean-percentage of total apoptotic cells from 3 independent 
experiments. *p<0.05 compared to control. 
 
In accordance with this, caspase-3 activity was significantly higher in FAT1 
suppressed cells compared to control cells with serum starvation (Figure 4.28).  
 
 
Figure 4.28 Analysis of caspase-3/7 activity in FAT1 suppressed (FAT1 shRNA#1, FAT1 
shRNA#2) and mock transfected (ctrl) HCC cells after serum starvation. *p<0.05 compared to 
control. 
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4.2.3 Function of FAT1 in HCC cells in vivo in the nude mouse model 
To test the effect of FAT1 on tumor growth in vivo, HCC cells stably suppressing 
FAT1 were injected subcutaneously into nude mice. Tumors derived from FAT1 
suppressing HCC cell clones showed delayed tumor onset compared to tumors 
derived from mock transfected control cells (Figure 4.29).  
 
 
Figure 4.29 Onset of tumors derived from FAT1 suppressed (FAT1 shRNA, n=9) or control cells 
(ctrl, n=8) implanted in nude mice. *p<0.05 compared to control. 
 
Expression analysis revealed preservation of FAT1 mRNA suppression in tumors 
derived from FAT1 suppressed cell clones compared to controls (Figure 4.30).  
 
 
Figure 4.30 FAT1 mRNA expression in tumors derived from FAT1 suppressed HCC cells (FAT1 
shRNA) and control cells (ctrl). *p<0.05 compared to control. 
 
Further, we analyzed the proliferation rate by immunohistochemical staining for 
Ki67 in the tumor tissue. Ki67 labeling revealed very high mitogenic activity in both 
tumors derived from FAT1 suppressed and control cells. Therefore no significant 
difference in the proliferation rate could be observed (Figure 4.31). 
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Figure 4.31 Immunohistochemical staining of Ki67 in tumors derived from control-transfected cells 
(left panel) or from FAT1 suppressed cell clones (right panel) (magnification 100x). 
 
Analysis of apoptotic cells by using the terminal deoxynucleotidyl transferase 
dUTP nick-end labeling system (TUNEL staining) showed only few apoptotic cells 
in control-transfected HCC derived tumors, whereas the FAT1 suppressing tumors 
displayed large apoptotic areas (Figure 4.32).  
 
 
Figure 4.32 Analysis of apoptotic cells in tumor tissue derived from control transfected cells (ctrl) 
and FAT1 suppressed cell clones (FAT1 shRNA) using TUNEL staining (green) and DAPI staining 
for nuclei (blue) (magnification 40x). 
 
In summary, data obtained in nude mice indicate that enhanced FAT1 expression 
induces tumorigenicity of HCC cells. 
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4.2.4 Regulation of FAT1 expression 
4.2.4.1 Effect of activated HSCs on FAT1 expression in HCC cells 
Our group has shown that hepatic stellate cells (HSCs) secrete factors by which 
they promote HCC progression via different signal cascades (Amann et al. 2009a). 
This prompted us to examine the effect of conditioned media (CM) from activated 
HSCs on FAT1 mRNA expression in HCC cells. Quantitative RT-PCR showed an 
increase of FAT1 mRNA after incubating HepG2 cells with CM (Figure 4.33).  
 
 
Figure 4.33 FAT1 mRNA expression in HepG2 cells stimulated with conditioned media from 
activated HSCs (CM) and control media (ctrl). *p<0.05 compared to control. 
 
In search for the factors in CM of activated HSCs responsible for FAT1 
upregulation we focused on hepatic growth factor (HGF), a factor known to act 
protumorigenic during hepatocancerogenesis. Stimulation of HCC cells with HGF 
induced a dose-dependent upregulation of FAT1 mRNA expression (Figure 4.34). 
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Figure 4.34 Analysis of FAT1 mRNA expression in HCC cells stimulated with different 
concentrations of HGF. *p<0.05 compared to control. 
 
Western Blot analysis confirmed induction of FAT1 expression in HCC cells by 
HGF on protein level (Figure 4.35). 
 
Figure 4.35 Analysis of FAT1 protein expression incubated with HGF [50 ng/ml]. 
 
Preincubation of CM of activated HSCs with anti-HGF antibodies completely 
abrogated the stimulating effect on FAT1 (Figure 4.36). 
 
 
Figure 4.36 Effect of anti-HGF antibodies on FAT1 mRNA expression in the presence of CM. CM 
was preincubated with anti-HGF antibodies or isotype marched control antibodies (ctrl IgG). 
Stimulation with HGF (50 ng/ml) revealed a similar effect as CM. *p<0.05 compared to control; 
# p<0.05 compared to CM. 
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Together, these data indicate that activated HSCs induce FAT1 expression in 
HCC cells via HGF.  
4.2.4.2 Regulation of FAT1 expression in HCC cells under anaerobic 
conditions 
HGF has been shown to enhance hypoxia inducible factor 1 alpha (HIF1α) activity 
in HCC cells (Tacchini et al. 2001). This transcription factor is an important 
mediator of hypoxic adaption of tumor cells and promotes tumorigenicity (Kim et 
al. 2002). Induction of hypoxia by incubating the cells with reduced oxygen 
concentration (1%) or by incubation with the chemical inducer Dipyridyl (DP) 
caused a significant upregulation of FAT1 mRNA expression in HCC cells (Figure 
4.37). Interestingly, Western Blot analysis demonstrated stabilization of HIF1α in 
DP treated cells (Figure 4.38). 
 
 
Figure 4.37 Analysis of FAT1 mRNA expression in HCC cells cultured under normoxic conditions, 
with pharmaceutical induction of hypoxia (DP, 100 µmol/L) or 1% oxygen (1% O2). *p<0.05 
compared to control. 
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Figure 4.38 FAT1 and HIF1α protein expression after chemical induction of hypoxia by DP 
(100 µmol/L). 
 
Further, FAT1 upregulation under DP-induced hypoxia was strongly repressed by 
echinomycin (Ech), a pharmaceutical inhibitor of HIF1α activity (Kong et al. 2005) 
(Figure 4.39). 
 
 
Figure 4.39 FAT1 mRNA expression with or without pharmaceutical induction of hypoxia (DP, 
100 µmol/L) and HIF1α inhibition with echinomycin (Ech, 10 nmol/L).*p<0.05 compared to control.  
 
In line with this finding, transient transfection with a dominant-negative variant of 
HIF1α (dnHIF1α) (Warnecke et al. 2004) led to diminished hypoxia induced FAT1 
expression (Figure 4.40). 
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Figure 4.40 Analysis of FAT1 mRNA after transfection of HCC cells with a dominant-negative 
variant of HIF1α (dnHIF1α) or a control plasmid (ctrl) with or without stimulation with DP 
(100 µmol/L). *p<0.05 compared to control.  
 
In silico analysis of the FAT1 promoter did not shown an HIF1 binding site (Tess, 
http://www.cbil.upenn.edu/cgi-bin/tess/tess?RQ=WELCOME;Genomatix software). 
Furthermore, costimulation with cycloheximide, an inhibitor of protein synthesis, 
abolished hypoxia-induced upregulation of FAT1 mRNA expression in HCC cells 
(Figure 4.41). 
 
Figure 4.41 FAT1 mRNA expression in DP (100 µmol/L) stimulated cells with or without blocking 
protein synthesis by cycloheximide (Cyclo, 50 µg/ml). *p<0.05 compared to control; #p<0.05 
compared to DP. 
 
Together, these data indicated that hypoxia or HIF1α, respectively, do not directly 
induce FAT1 expression on transcriptional level. It is known that hypoxia can 
cause epigenetic modifications as demethylation (Shahrzad et al. 2007). Of note, 
incubation with 5-azacytidine (Aza) and adenosine periodate oxidized (Adox), 
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inhibitors of DNA methylation, caused a dose-dependent upregulation of FAT1 
expression in HCC cells (Figure 4.42). 
 
 
Figure 4.42 Fat1 mRNA expression in HCC treated with different doses of 5-azacytidine (Aza) and 
Adenosine periodate oxidized (Adox). *p<0.05 compared to control.  
 
These data suggested that hypoxia induced FAT1 expression may also be caused 
by demethylation. Most recently, it has been shown by Liu et al., that hypoxia 
induced DNA demethylation in HCC is caused through activation of HIF1α and 
transcriptional upregulation of methionine adenosyltransferase II, alpha (MAT2A). 
Consecutively, increased MATII activity leads to reduced levels of the methyl 
donor S-adenosylmethionine (SAM) (Liu et al. 2011). Also we observed reduced 
SAM-levels in the supernatant of HCC cells in chemical hypoxia (Figure 4.43). 
 
 
Figure 4.43 Analysis of S-adenosylmethionine (SAM) level in the supernatant of HCC cells after 
induction of hypoxia with DP (100 µmol/L) for 24 h. *p<0.05 compared to control. 
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Replenishment of SAM in culture medium of HCC cells dose-dependently inhibited 
hypoxia induced FAT1 expression (Figure 4.44). Cells were stimulated with higher 
concentrations of SAM than found in the supernatant, but in the literature even 
higher doses for stimulation of HCC cells can be found (Ou et al. 2007; Yang et al. 
2004)  
 
 
Figure 4.44 FAT1 mRNA expression in HCC cells stimulated with different doses of 
S-adenosylmethionine (SAM). Subsequently cells were stimulated with DP (100 µmol/L) to induce 
hypoxia (DP). *p<0.05 compared to control, #p<0.05 compared to DP. 
 
These findings indicate that hypoxia induced FAT1 expression in HCC cells via 
MAT2A induced SAM depletion and subsequent demethylation. 
To verify these findings in vivo we assessed FAT1 and vascular endothelial growth 
factor (VEGF) expression in 25 human HCC specimens. VEGF is highly regulated 
by HIF1α in HCC (Huang et al. 2005), and notably, we found a significant 
correlation between VEGF and FAT1 expression in HCC tissues Furthermore, 
FAT1 and MAT2A expression showed a significant correlation in HCC (Figure 
4.45). 
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Figure 4.45 Correlation of FAT1 with vascular endothelial growth factor (VEGF, left panel) and 
methionine adenosyltransferase II, alpha (MAT2A, right panel) mRNA expression in HCC tissue 
(n=24). 
 
Together, these data suggested that also in vivo hypoxia is a critical regulator of 
FAT1 expression in HCC. This effect seems to be at least in part mediated via 
enhanced MAT2A expression and subsequent depletion of SAM levels leading to 
demethylation of the FAT1 promoter.  
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5 Discussion 
FAT1 is a member of the atypical cadherin family and has been implicated in 
various biological processes such as cell polarity, proliferation, and migration (see 
chapter 2.6.1.1). Cancer research revealed deregulated FAT1 expression (see 
chapter 2.6.1.2).  
The aim of this thesis was to investigate FAT1 in the liver based on the fact that up 
till now no data addressing this issue existed. In particular, we analyzed FAT1 
expression and function in chronic liver disease and hepatic stellate cells as 
central mediators of hepatic fibrosis as well as FAT1 expression and function in 
hepatocellular carcinoma in vitro and in vivo.  
 
The discussion is divided into two main chapters according to the arrangement of 
the results in chapter 4: 
 
5.1 FAT1 and chronic liver disease 
5.2 FAT1 and hepatocellular carcinoma 
5.1 FAT1 and chronic liver disease 
While in healthy adult liver hepatocytes reveal only a minimal replication rate, they 
start to proliferate in response to liver injury (Taub 2004). We observed a marked 
upregulation of FAT1 expression in different murine models of liver injury as well 
as in diseased human livers. Unexpectedly, immunohistochemistry revealed no 
significant increase of FAT1 expression in hepatocytes of diseased livers 
compared to healthy control livers. However and interestingly, a strong 
immunosignal was observed in myofibroblast-like cells in fibrotic septa of cirrhotic 
livers, and we found a strong upregulation in HSCs during in vitro activation. 
Moreover, hepatic FAT1 expression revealed a striking correlation with the 
expression of collagen alpha I(1), the major component of type I collagen. Upon 
hepatic injury this fibrillar collagen is produced by activated HSCs and constitutes 
the most abundant extracellular matrix protein in fibrotic liver tissue. Together 
these data strongly indicate activated HSCs as the cellular source of increased 
FAT1 expression in diseased livers. A previous study showed increased FAT1 
expression in injured arteries and identified vascular smooth muscle cells as 
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cellular source (Hou et al. 2006). In vascular injury as well as in chronic kidney 
disease and an epithelial cell wound model FAT1 seems to be necessary for 
efficient wound healing. Also HSC activation and hepatic fibrosis can be 
considered as physiological wound healing process in response to acute hepatic 
injury. However, upon persistent hepatocellular injury excessive or dysregulated 
fibrosis leads to a distortion of the hepatic architecture and can lead to severe 
organ dysfunction. The correlation between FAT1 and collagen alpha I (1) 
expression and the increased expression during HSC activation strongly suggest 
that this atypical cadherin also plays a critical role in hepatic fibrosis. Furthermore, 
we newly link FAT1 expression to apoptosis resistance in activated HSCs. We and 
others have shown that the activation of the transcription factor NFκB markedly 
increases during HSC activation and strongly contributes to the resistance to 
apoptosis in activated HSCs (Hellerbrand et al. 1998; Oakley et al. 2005). Notably, 
we found that suppression of FAT1 led to a significant reduction of NFκB-activity in 
activated HSCs. This strongly indicates that the effect of FAT1 on apoptosis is at 
least in part mediated via NFκB activation.  
Although fibrosis is a progressive pathological process there is emerging 
experimental and clinical evidence that even cirrhosis is potentially reversible. Key 
to this is the discovery that reversion of fibrosis is accompanied by clearance of 
activated HSCs by apoptosis (Elsharkawy et al. 2005).  
5.2 FAT1 and hepatocellular carcinoma 
The specific function of FAT1 in cancer development and progression is still under 
investigation. There are contrasting studies about the role of FAT1 in human 
cancers, pointing towards a dual role of FAT1 as both an oncogene as well as a 
tumor suppressor (Kwaepila et al. 2006; Settakorn et al. 2005). Here, we found 
increased FAT1 expression in HCC cells and tissues compared to primary human 
hepatocytes and non-tumorous liver tissue, and strong FAT1 expression 
significantly correlated with higher tumor stages and higher mitotic activity. These 
findings indicated a protumorigenic effect of FAT1 in HCC, and functional studies 
confirmed that FAT1 promotes the tumorigenicity of HCC cells in vitro and in vivo. 
FAT1 has been shown to affect different biological mechanisms. Similar as 
described in squamous cell carcinoma and glioma cells, we observed reduced 
migratory potential in HCC cells upon FAT1 suppression (Chosdol et al. 2009; 
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Dikshit et al. 2012), while FAT1 seems to inhibit progression to invasive phenotype 
in breast cancer (Lee et al. 2012). In cholangiocarcinoma, Settakorn et al. found 
that FAT1 expression showed a significant inverse association with the Ki67 index 
and that loss of membrane localization for FAT1 correlated with more aggressive 
tumors (Settakorn et al. 2005). In non-malignant vascular smooth muscle cells 
FAT1 knockdown decreased migration in vitro, but surprisingly and in contrast to 
our findings in HCC cells, enhanced proliferation in vitro (Hou et al. 2006).  
These findings indicate varying effects of FAT1 on proliferation and migration in 
different cell types. FAT1 has also been engaged in several other biological 
functions as cell polarity (Moeller et al. 2004), but available literature had not yet 
functionally linked FAT1 to apoptosis. Here, we demonstrated that FAT1 
downregulation impairs the resistance of HCC cells against induced apoptosis in 
vitro, and also in vivo tumors derived from FAT1 cells with repressed FAT1 
expression revealed significantly more apoptotic cells than tumors derived from 
control cells. Together these data indicate that increased FAT1 expression in HCC 
acts protumorigenic.  
In search for the molecular mechanism responsible for the transcriptional 
upregulation of FAT1 in HCC we first looked at factors secreted by activated 
hepatic stellate cells. These cells do not only form and infiltrate the HCC stroma 
(Dubuisson et al. 2001; Faouzi et al. 1999; Le Bail B. et al. 1999), but also induce 
tumorigenicity in HCC cells in vitro and in vivo (Amann et al. 2009a). We identified 
HGF as a strong inducer of FAT1 expression in HCC cells. The exact role of HGF 
in HCC development and progression has not yet been defined. On the one hand, 
the growth of different HCC cell lines was reduced in the presence of HGF (Shiota 
et al. 1992; Tajima et al. 1991), and transgenic animals expressing HGF in the 
liver inhibited hepatocarcinogenesis in bitransgenic mice overexpressing c-myc 
(Santoni-Rugiu et al. 1996) or transforming growth factor alpha (TGFα) (Shiota et 
al. 1995). On the other hand, HGF transgenic mice which are overexpressing HGF 
more rapidly developed HCC in the DEN model of chemically induced 
hepatocancerogenesis (Horiguchi et al. 2002).  
We found that HGF effects on FAT1 activation are not mediated via the classical 
HGF-c-Met signaling pathway but via increased activation of HIF1α. Activation of 
this transcription factor has been shown to play a critical role in HCC progression 
(Huang et al. 2005; Kim et al. 2002; Tanaka et al. 2006). In addition to HGF 
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induction HIF1α is typically stabilized and herewith leads to an activation of this 
pathway by hypoxia. Hypoxic conditions frequently occur in tumor tissue and are 
another critical promoter of HCC progression (Rosmorduc and Housset 2010). 
Interestingly, we found that hypoxia and HIF1α effects, respectively, on FAT1 
expression are not mediated on the transcriptional level but epigenetic 
mechanisms. Specifically, we found that hypoxia leads to reduced levels of the 
methyl donor S-adenosylmethionine (SAM) in HCC cells, and replenishment of 
SAM abrogates hypoxia induced FAT1 expression in HCC cells in vitro. A recent 
study by Liu et al. identified HIF1α dependent upregulation of methionine adenosyl 
transferase 2A (MAT2A) as novel mechanism how hypoxia induces DNA 
demethylation (Liu et al. 2011).  
Methionine adenosyltransferase is the only enzyme responsible for the reaction 
from methionine and ATP to SAM. There are two genes (MAT1A, MAT2A) for two 
homologous catalytic MAT subunits (MATI, MATII). While MAT1A is mainly 
expressed in healthy liver, during the progression of HCC a switch from MAT1A to 
MAT2A takes place (Cai et al. 1996). This leads to reduced SAM levels due to the 
lower enzymatic activity of MATII compared to MATI (Lu and Mato 2008). 
Here, we found that incubation with demethylating agents significantly enhanced 
FAT1 expression in HCC cells in vitro and observed a significant correlation 
between FAT1 and MAT2A in HCC tissues. A model of FAT1 regulation in HCC 
cells can be postulated as follows: HGF induced or hypoxia mediated HIF1α 
activation enhances MAT2A expression. Consecutively, increased MATII activity 
and consequently reduced MATI activity in summary  cause reduced levels of the 
methyl donor SAM, and subsequently, reduced methylation including the FAT1 
promoter and higher FAT1 expression, respectively. This working model is 
summarized in Figure 5.1 
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Figure 5.1 Working model for regulation of FAT1 expression in HCC cells. HGF secreted from 
activated hepatic stellate cells (aHSC) or hypoxia stabilizes HIF1α which transcriptionally 
upregulates MAT2A expression. Enhanced MATII activity causes reduced levels of the methyl 
donor S-adenosylmethionine (SAM), which leads to reduced methylation of the FAT1 promoter, 
and higher FAT1 transcription. 
 
HGF has been linked to the polyamine pathway via NFκB regulated ornithine 
decarboxylase (ODC) expression (Tacchini et al. 2004). Recent studies 
demonstrated the regulatory role of SAM in HGF-mediated hepatocytes 
proliferation through a mechanism that implicates the activation of the non-
canonical LKB1/AMPK/eNOS cascade and the function of HuR, which stabilizes 
MAT2A mRNA (Gomez-Santos et al. 2012). Here, we newly demonstrate a novel 
regulatory pathway by which HGF can effect SAM levels and herewith promoter 
methylation and transcription of the atypical cadherin FAT1. 
Four FAT genes have now been identified in vertebrates, and Sopko and 
coworkers (Sopko et al. 2009) have shown that mammalian FAT4 is the true 
structural orthologues of Drosophila Fat, which has been identified as regulator of 
the Hippo pathways (Bennett and Harvey 2006). Despite this, several studies 
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suggest that FAT1 also shares the functional role as regulator of the Hippo 
pathway at least during development (Skouloudaki et al. 2009). The Hippo 
signaling pathway has a conserved role in growth control and is of fundamental 
importance during both normal development and oncogenesis. Thus, this pathway 
also has a prominent role in suppressing tumor growth, with the most evident 
contribution in HCC (Liu et al. 2012). FAT1 may be a mediator linking HGF and 
hypoxia induced HIF1α activation with this complex yet important growth-control 
signaling pathway. 
Signaling pathways propagated from the cell surface through transmembrane 
receptors to intracellular regulatory mechanisms are critical from normal as well as 
aberrant cellular functions. Here, we demonstrated that increased FAT1 
expression in HCC induces proliferation, migration and resistance to apoptosis. 
The FAT1 effect on apoptosis is a novel finding as well as the identification of 
FAT1 as potential mediator of hypoxia and growth receptor signaling to critical 
HCC related mechanisms.  
5.3 Conclusion 
In this work it could be shown that FAT1 is overexpressed in hepatocellular 
carcinoma and promotes its tumorigenicity. Furthermore, FAT1 is upregulated in 
human cirrhotic liver tissues, which represents a precancerous condition for HCC. 
Further, FAT1 was found to be increased during activation of hepatic stellate cells, 
i.e. an early event of the fibrosis-cirrhosis-carcinoma course. In these cells, FAT1 
is involved in apoptosis-resistance and proinflammatory gene expression of HSCs. 
In addition, we found that activated HSCs are able to induce FAT1 expression in 
HCC cells via secretion of HGF which represents another example for the 
protumorigenic interaction between HSCs in the tumor stroma and HCC.  
The fact that FAT1 is involved in different stages and mechanisms of liver disease 
progression suggests it as a novel and promising prognostic and therapeutic 
target. 
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7 Abbreviations 
α-sma alpha-smooth muscle actin 
°C degree Celsius 
µg microgram 
µl microliter 
µm micrometer 
µM micromolar 
µm micrometer 
Adox Adenosine-2′,3′-dialdehyde 
ALF acute liver failure 
ALL acute lymphatic leukemia 
AMV-RT avian myeloblastosis virus reverse transcriptase 
arb. arbituary 
APS ammonium persulfate 
ATP adenosine triphosphate 
Aza 5-Aza-2‘deoxycytidine 
BCA bicinchonic acid 
BDL bile duct ligation 
bp base pairs 
BSA bovine serum albumin 
ca. circa 
CAM cell adhesion molecule 
cDNA complementary DNA 
coll I collagen type I 
ctrl. control 
Cyclo Cycloheximide 
d day 
Da dalton (=1.66018 x 10-24 g) 
DAPI 4’, 6-diamino-2-phenylindole 
dest. destilled 
DMEM Dulbecco’s modified eagle medium 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DP 2,2-dipyridyl 
e.g. exempli gratia 
ECM extracellular matrix 
EDTA ethylene diamine tetraacetic acid 
EGTA ethylene glycol tetraacetic acid 
ELISA enzyme linked immunosorbent assay 
EMT epithelial-mesenchymal transition 
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FCS fetal calf serum 
FITC fluorescein isothiocyanate 
g gram 
h hour 
H2Odest. destilled water 
HCC hepatocellular carcinoma 
HGF hepatocyte growth factor 
HIF hypoxia inducible factor 
HRP horse radish peroxidase 
HSC hepatic stellate cells 
hTERT human telomerase reverse transcriptase 
Ig immunoglobulin 
IκBα inhibitory kappa B alpha 
kDa kilodalton 
l liter 
LOH loss of heterozygosity 
LSEC liver sinusoidal endothelial cells 
M molar, mol/l 
mA milliampere 
MCP-1 monocyte chemoattractant protein-1 = CCL2 
MET mesenchymal-epithelial transition 
mg milligram 
Mg magnesium 
min minute 
ml milliliter 
mM millimolar 
mm millimeter 
mmol millimol 
MMP matrix metalloproteinase 
mRNA messenger RNA 
NAFLD non-alcoholic fatty liver disease 
NASH non-alcoholic steatohepatitis 
NFκB nuclear factor kappa B 
ng nanogram 
NLS nuclear localization sequence 
nm nanometer 
OD optical density 
OSCC oral squamous cell carcinomas 
PBC primary biliary cirrhosis 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
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PDGF platelet-derived growth factor 
PEI percutaneous ethanol injection 
pH pondus hydrogenii 
PHH primary human hepatocytes 
PI propidium iodide 
PCP planar cell polarity 
PMH primary murine hepatocytes 
PSC primary sclerosing cholangitis 
p-value probability value (statistics) 
qRT-PCR quantitative realtime-PCR 
r radius 
RFA radiofrequency ablation 
RNA ribonucleic acid 
RNase ribonuclease 
ROS reactive oxygen species 
rpm rounds per minute 
RT room temperature 
s second 
SDS sodium dodecyl sulfate 
SIRT selective internal radiation therapy 
STS staurosporine 
TAA thioacetamide 
TACE transarterial chemoembolization 
TE tris EDTA 
TEMED N, N, N’, N’-tetramethylethylenediamine 
TIMP tissue inhibitors of matrix metalloproteinases 
TMA tissue microarray 
TNF tumor necrosis factor 
Tris tris(hydroxymethyl)aminomethane 
TWEEN Polyoxyethylene sorbitan monolaurate 
U unit 
U.S. United States 
UV ultraviolet 
V volt 
v/v volume per volume 
VEGF vascular endothelial growth factor 
Vol. volume 
vs. versus 
VSMC vascular smooth muscle cells 
w/v weight per volume 
XTT 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-
[phenylamino)carbonyl]-2H-tetrazolium hydroxide 
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 Valletta D., Czech B., Weiss T.S., Bosserhoff A.K., Hellerbrand C. 
FAT1 expression is increased in hepatocellular carcinoma and promotes 
tumorigenesis 
8.4.2 Poster presentations 
26. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der 
Leber (29. – 30. Jan. 2010, Bonn, Germany) 
 Valletta D., Amann T., Bosserhoff A., Hellerbrand C. 
Increased expression of FAT1 in hepatocellular carcinoma promotes 
tumorigenicity 
33rd Annual Meeting of the German Society for Cell Biology (10. – 13. March 
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Falk Workshop, Inflammation & Cancer (26. – 27. Jan. 2012, Hamburg, 
Germany) 
 Valletta D., Czech B., Hellerbrand C 
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